

TUTOGEN MEDICAL INC

Form S-1

December 29, 2006

Table of Contents

As filed with the Securities and Exchange Commission on December 29, 2006

Registration No. 333-_____

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-1
REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OF 1933
TUTOGEN MEDICAL, INC.
(Name of small business issuer in its charter)**

Florida

5047 8731

59-3100165

(State or jurisdiction of
incorporation or organization)

(Primary Standard Industrial
Classification Code Number)

(I.R.S. Employer
Identification No.)

**13709 Progress Boulevard, Alachua, Florida 32615
Telephone: (386) 462-0402**

(Address and telephone number of principal executive offices)

13709 Progress Boulevard, Alachua, Florida 32615

(Address and principal place of business or intended principal place of business)

**Guy Mayer, President
13709 Progress Boulevard
Alachua, Florida 32615
Telephone: (386) 462-0402**

(Name, address and telephone number of agent for service)

Copy of Communications to:

**Williams Schifino Mangione & Steady, P.A.
Attn: William J. Schifino, Sr., Esq.
One Tampa City Center, Suite 3200, Tampa, Florida 33602
Telephone: (813) 221-2626**

Approximate date of proposed sale to the public: From time to time after the effective date of this registration statement.

If any securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.

If delivery of the prospectus is expected to be made pursuant to Rule 434, check the following box.

CALCULATION OF REGISTRATION FEE

Title of each class of securities to be registered	Amount to be registered⁽¹⁾	Proposed maximum offering price per unit⁽²⁾	Proposed maximum aggregate offering price	Amount of registration fee⁽²⁾
Common Stock	582,524 shs. ⁽³⁾	\$7.15	\$4,165,047	\$446
	175,000 shs. ⁽⁴⁾	\$7.15	\$1,251,250	\$134
Total	757,524 shs.		\$5,416,297	\$580

(1) An indeterminate number of additional shares of common stock shall be issuable pursuant to Rule 416 to prevent dilution resulting from stock splits, stock dividends or similar transactions and in such an event the number of shares registered shall automatically be increased to cover the additional shares in accordance with Rule 416 under the Securities Act.

(2) Estimated for the sole purpose of calculating the registration fee pursuant to Rule 457(c) of the Securities Act of 1933, as amended and based upon the

closing price of
our common
stock on
December 21,
2006, as
reported on the
American Stock
Exchange.

- (3) Represents
shares issuable
upon conversion
of a
subordinated
convertible
debenture. In
accordance with
the terms of the
debenture, the
number of
shares included
herein was
determined
assuming:
(i) conversion of
the entire
\$3,000,000
principal
amount under
the convertible
debenture at a
conversion price
of \$5.15 per
share.

- (4) Represents
shares issuable
upon exercise of
warrants.

THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON THE DATE OR DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF THE SECURITIES ACT OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME EFFECTIVE ON THE DATE AS THE COMMISSION, ACTING PURSUANT TO SAID SECTION 8(A), MAY DETERMINE.

Table of Contents

PROSPECTUS

**Subject to Completion
December 29, 2006**

**703,535 SHARES
TUTOGEN MEDICAL, INC.
COMMON STOCK**

This prospectus relates to the resale by the Azimuth Opportunity, Ltd., a British Virgin Islands corporation, (Azimuth or the Selling Stockholder) of up to 757,524 shares of our common stock. Of the shares being offered hereby, up to 582,524 shares are issuable upon conversion of a \$3,000,000 subordinated convertible debenture held by Azimuth and 175,000 shares are issuable upon the exercise of warrants granted to Azimuth in connection with a loan of \$3,000,000 made to the Company in June 2006. We will not receive any proceeds from the sale of shares of common stock by the Selling Stockholder. We will, however, receive proceeds from the exercise, if any, of the warrants to purchase 175,000 shares. All costs associated with the registration of the shares will be borne by us.

Azimuth may be deemed an underwriter within the meaning of the Securities Act of 1933 in connection with the sale of the common stock covered hereby. With the exception of Azimuth, no other underwriter or person has been engaged to facilitate the sale of shares of common stock in this offering. The Selling Stockholder may offer to sell the shares of common stock at fixed prices, at prevailing market prices at the time of sale, at varying prices or at negotiated prices.

Our common stock is quoted on the American Stock Exchange (AMEX) under the symbol TTG . On December 21, 2006, the closing price for our common stock was \$7.15 per share.

Our business is subject to many risks and an investment in our common stock will involve a high degree of risk. You should carefully consider the various risk factors described herein beginning on page 5 before investing in our common stock.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

This prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

The date of this prospectus is _____, 2007

TABLE OF CONTENTS

	Page
<u>Prospectus Summary</u>	2
<u>Risk Factors</u>	5
<u>The Offering</u>	9
<u>Use of Proceeds</u>	9
<u>Market for Common Stock</u>	10
<u>Selected Consolidated Financial Data</u>	11
<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	12
<u>Description of Business</u>	20
<u>Management</u>	31
<u>Security Ownership of Certain Beneficial Owners and Management</u>	41
<u>Selling Stockholders</u>	42
<u>Plan of Distribution</u>	42
<u>Description of Capital Stock</u>	43
<u>Legal Matters</u>	44
<u>Experts</u>	44
<u>Where You Can Find More Information</u>	44
Financial Statements	F-1
<u>EX-5.1 OPINION OF COUNSEL</u>	
<u>EX-10.14 COPY OF DISTRIBUTION AGREEMENT</u>	
<u>EX-10.15 COPY OF DISTRIBUTION AGREEMENT</u>	
<u>EX-10.16 COPY OF ASSIGNMENT AGREEMENT</u>	
<u>EX-23.1 CONSENT OF ACCOUNTING FIRM</u>	

FORWARD-LOOKING STATEMENTS

This prospectus contains forward-looking statements, which relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts" or "potential" or the negative of these terms or other terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks in the section entitled "Risk Factors" that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We base our forward-looking statements on information currently available to us, and we assume no obligation to update them. Statements contained in this Prospectus that are not historical facts are forward-looking statements that are subject to the "safe harbor" created by the Private Securities Litigation Reform Act of 1995.

Table of Contents

PROSPECTUS SUMMARY

This summary highlights information contained elsewhere in this prospectus. You should read the entire prospectus carefully; including the section entitled Risk Factors before deciding to invest in our common stock. As used in this prospectus, Tutogen Medical, Inc. may be referred to as we, us, our, Company and Tutogen .

Our Company

Tutogen Medical, Inc., a Florida corporation, was formed in 1985 and with its consolidated subsidiaries (collectively, the Company or Tutogen), designs, develops, processes, manufactures and markets sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Surgeons use our products to repair and promote the healing of a wide variety of bone and other tissue defects, including dental, spinal, urology, ophthalmology, head, neck and general surgery procedures. Our products are distributed throughout the United States and in over twenty (20) other countries.

The Company contracts with independent tissue banks and procurement organizations to provide donated human tissue for processing under the Company s proprietary *Tutoplast*® process. The *Tutoplast*® process utilizes solvent dehydration and chemical inactivation which is applied to two types of preserved allografts: soft tissue; consisting of fascia lata, fascia temporalis, pericardium, dermis, sclera and bone tissue; consisting of various configurations of cancellous and cortical bone material. The *Tutoplast*® processed allografts have been used successfully in more than 1,500,000 procedures performed over the last thirty (30) years.

We pursue a market approach to the distribution of our implants and establish strategic distribution arrangements in order to increase our penetration in selected markets. We have distribution agreements with Zimmer Dental, Inc. (Zimmer Dental) and Zimmer Spine, Inc. (Zimmer Spine), subsidiaries of Zimmer Holdings, Inc. (Zimmer Holdings) for the dental and spine markets, Mentor Corporation for breast reconstruction, IOP, Inc. for ophthalmology, Davol, Inc. for hernia, Coloplast Corporation for urology and Sense Medical LLC for ears, nose and throat. In the international markets that we serve, we use a network of independent distributors.

We estimate the worldwide market for our present products exceeds \$1.25 billion, including all procedures in the field of use. The Company s existing tissue supply network, established processing facilities and proven *Tutoplast*® technology provide the foundation for continued revenue growth into fiscal 2007 and beyond. The future growth may be aided by new sources of tissue, new applications and products and expansion into new markets.

The Company operates two (2) tissue processing facilities: a 26,000 square foot facility in Alachua, Florida and a 33,000 square foot facility in Neunkirchen, Germany. The Alachua, Florida facility is a U.S. Food and Drug Administration registered medical device and biological establishment and is accredited by and a member of the American Association of Tissue Banks. The Neunkirchen, Germany facility is certified according to ISO9001 and EN4600, and is registered as a biological establishment with the U.S. Food and Drug Administration

The Company s executive officers are located at 13709 Progress Boulevard, Alachua, Florida 32615, telephone number (386) 462-0402.

Table of Contents

The Offering

On June 30, 2006, the Company issued to Azimuth, an institutional investor, a \$3.0 million convertible debenture and warrants for the purchase up to 175,000 shares of common stock for gross proceeds of \$3.0 million.

Pursuant to the terms of the securities purchase agreement, the debenture is convertible into shares of common stock at \$5.15 per share, or 582,524 shares, at any time prior to August 1, 2007. In addition, the warrants are exercisable at a price of \$5.15 per share at any time at the election of the holder until the earlier of the third anniversary of the date of issuance or upon a change in control of the Company. The debenture, which bears interest at the rate of five percent (5.0%) per year (payable quarterly in arrears), is due August 1, 2007 or upon a change in control of the Company. The debenture is unsecured and ranks junior to all of the Company's existing indebtedness and senior to any additional indebtedness. In addition, the terms of the debenture and warrants provide for anti-dilution adjustments to the conversion and exercise prices in the event that the Company issues equity securities at a price below \$5.15 within twelve (12) months from the date of issuance, other than in connection with specified exempt issuances. The \$5.15 conversion and exercise prices represent a premium to the market price of Tutogen's common stock on the day prior to the closing of the loan. The Company used the proceeds from the financing for general corporate purposes.

In connection with the financing, the Company entered into a registration rights agreement, under which the Company agreed to file a registration statement with the Securities and Exchange Commission for the resale of the shares of common stock underlying the debenture and the warrant sold in the private placement upon the earlier of December 31, 2006 or the day following the filing of the Company's Annual Report on Form 10-K for the fiscal year ending September 30, 2006. Failure to file the registration statement in a timely manner results in payment by the Company to Azimuth of penalties, subject to certain limitations. Such penalties are also payable in the event that the resale registration statement has not been declared effective within certain time periods or if sales cannot be made pursuant to the registration statement following its effectiveness.

Number of Shares to be Outstanding after the Offering

As of November 30, 2006, 16,413,815 shares of our common stock were outstanding. Assuming the issuance of all of the shares covered by this offering, there will be 17,171,339 shares of our common stock issued and outstanding.

Estimated Use of Proceeds

The shares of common stock offered by this prospectus are being registered for the account of Azimuth. As a result, all proceeds from the sale of the common stock by Azimuth will go to the Selling Stockholder and we will not receive any proceeds from such sale. We will, however, receive proceeds from the exercise, if any, of the warrant to purchase 175,000 shares of common stock. Any proceeds we receive from the exercise of the warrants will be used for working capital purposes.

Table of Contents**Summary of Financial Data**

The summarized financial data presented below is derived from and should be read in conjunction with our audited financial statements for the fiscal years set forth below. The following data should also be read in conjunction with the information contained in the section entitled Management's Discussion and Analysis of Financial Condition and Results of Operations included elsewhere in this prospectus.

	Year Ended September 30,				
	2002	2003	2004	2005	2006
	(Dollars in thousands, except per share data)				
Revenue	\$ 20,747	\$ 30,260	\$ 29,330	\$ 31,860	\$ 37,947
Gross margin %	60%	67%	60%	37%	57%
Operating (loss) income	1,666	5,265	3,158	(7,227)	(287)
Net (loss) income	901	3,707	1,133	(7,017)	(589)
Basic earnings (loss) per share	0.06	0.24	0.07	(0.44)	(0.04)
Diluted earnings (loss) per share	0.06	0.23	0.07	(0.44)	(0.04)
Average shares outstanding for basic (loss) earnings per share	15,114,000	15,495,148	15,734,470	15,919,286	16,027,469
Average shares outstanding for diluted (loss) earnings per share	15,960,000	16,095,448	16,469,443	15,919,286	16,027,469

	September 30,				
	2002	2003	2004	2005	2006
Balance Sheet Data:					
Working capital	\$10,856	\$15,342	\$17,471	\$ 8,433	\$ 8,215
Total assets	23,748	29,962	33,536	26,205	38,917
Long-term debt	693	728	827	814	4,770
Stockholders' equity	13,928	17,606	21,272	13,722	15,221

The Company adopted SFAS No. 123R in the year ended September 30, 2006. The impact of this adoption is discussed in Management's Discussion and Analysis of Financial Condition and Results of Operations below within the General and Administrative Expenses section.

Table of Contents

RISK FACTORS

An investment in our common stock involves a number of very significant risks. You should carefully consider the following risks and uncertainties in addition to other information in this prospectus in evaluating our Company and its business before purchasing shares of our Company's common stock. Our business, operating results and financial condition could seriously be harmed due to any of the following risks. The risks described below are not the only ones facing our Company. Additional risks not presently known to us may also impair our business operations. You could lose all or part of your investment due to any of these risks.

We depend heavily upon a limited number of sources of human tissue, and any failure to obtain tissue from these sources in a timely manner will interfere with our ability to process and distribute allografts.

Our business is dependent on the availability of donated human cadaver tissue supplied by donor recovery groups. Donor recovery groups provide support to donor families, are regulated by the FDA, and are often affiliated with hospitals, universities or organ procurement groups. Our relationships with donor recovery groups, which are critical to our supply of tissue, can be affected by relationships they have with other organizations. Any negative impact of the regulatory and disease transmission issues facing the industry, as well as the negative publicity that these issues create, could have an impact on our ability to negotiate favorable contracts with recovery groups.

If our current sources can no longer supply human cadaveric tissue or our requirements for human cadaveric tissue exceed their current capacity, we may not be able to locate other sources on a timely basis, or at all. Any significant interruption in the availability of human cadaveric tissue would likely cause us to slow down the processing and distribution of our human tissue products, which could adversely affect our ability to supply the needs of our customers and materially and adversely affect our results of operations and our relationships with our customers. AlloSource, our largest donor recovery group, supplied us with approximately 65% of our total human tissue for the year ended September 30, 2006. Our three largest recovery groups together supplied approximately 83% of our total tissue for the year ended September 30, 2006. If we were to lose any one of these sources of tissue, the unfavorable impact on our operating results would be material.

We are highly dependent upon independent distributors to generate our revenues.

We currently derive the majority of our revenues through our relationships with two companies, Zimmer Dental and Zimmer Spine. For the year ended September 30, 2006, we derived approximately 46% and 8% of our consolidated revenues from distribution by Zimmer Dental and Zimmer Spine, respectively.

Zimmer Dental and Zimmer Spine each provide nearly all of the instrumentation, surgeon training, distribution assistance and marketing materials for our line of dental and spinal allografts. If our relationship with such companies is terminated or further reduced for any reason and we are unable to replace the relationship with other means of distribution, we would suffer a material decrease in revenues.

We face intense competition from companies, academic institutions, tissue banks, organ procurement organizations and tissue processors with greater financial resources and lower costs which could adversely affect our revenues and results of operations.

The biotechnology field is highly competitive and is undergoing rapid and significant technological changes. Our success depends upon our ability to develop and commercialize effective products that meet medical needs as well as our ability to accurately predict future technology and market trends.

Table of Contents

Many of our competitors have much greater financial, technical, research, marketing, distribution, service and other resources that are significantly greater than ours. Moreover, our competitors may offer a broader array of tissue repair treatment products and technologies or may have greater name recognition than we do in the marketplace.

Our competitors may develop or market technologies that are more effective or commercially attractive than ours, or that may render our technology uncompetitive, uneconomical or obsolete. For example, the successful development of a synthetic tissue product that permits remodeling of bones could result in a decline in the demand for allograft-based products and technologies and have a materially adverse effect on our financial condition and results of operation.

If third party payers fail to provide appropriate levels of reimbursement for the use of our implants, our revenues would be adversely affected.

Political, economic and regulatory influences are subjecting the healthcare industry in the United States to fundamental change. Any new Federal or state legislation could result in significant changes in the availability, delivery, pricing or payment for healthcare services and products. While we cannot predict what form any new legislation will take, it is possible that any significant healthcare legislation, if adopted, could lower the amounts paid to us for our services, which would decrease our revenues.

Our revenues depend largely on the reimbursement of patients' medical expenses by government healthcare programs and private health insurers. Governments and private insurers closely examine medical procedures incorporating new technologies to determine whether the procedures will be covered by payment, and if so, the level of payment which may apply. We cannot be sure that third party payers will continue to reimburse us or provide payment at levels which will be profitable to us.

Our allograft and xenograft implants and technologies could become subject to significantly greater regulation by the FDA, which could disrupt our business.

The FDA and several states have statutory authority to regulate allograft processing and allograft-based materials. The FDA could identify deficiencies in future inspections of our facilities or promulgate future regulatory rulings that could disrupt our business, hurting our profitability.

FDA regulations of human cellular and tissue-based products, titled "Good Tissue Practices," went into full effect as of May 2005. These regulations cover all stages of allograft processing, from procurement of tissue to distribution of final allografts. These regulations may increase regulatory scrutiny within our industry and lead to increased enforcement action which affects the conduct of our business. In addition, the effect of these regulations may have a significant effect upon recovery agencies which supply us with tissue and increase the cost of recovery activities. Any such increase would translate into increased costs to us, as we compensate the recovery agencies based on their cost of recovery.

Other regulatory entities include state agencies with statutes covering tissue banking. Of particular relevance to our business are regulations issued by Florida, New York, California and Maryland. Most states do not currently have tissue banking regulations. However, recent incidents of allograft related infections in the industry may stimulate the development of regulation in other states. It is possible that others may make allegations against us or against donor recovery groups or tissue banks, including those with which we have a relationship, about non-compliance with applicable FDA regulations or other relevant statutes and regulations. Allegations like these could cause regulators or other authorities to take investigative or other action, or could cause negative publicity for our business and our industry.

Table of Contents

Some of our implants in development will contain tissue derived from animals, commonly referred to as xenografts. Xenograft implants are medical devices that are subject to pre-market approval or clearance by the FDA. We may not receive FDA approval or clearance to market new implants as we attempt to expand the quantity of xenograft implants available for distribution.

The National Organ Transplant Act (NOTA) could be interpreted in a way that could reduce our revenues and income in the future.

Some aspects of our business are subject to additional local, state, federal or international regulation. Changes in the laws or new interpretations of existing laws could negatively affect our business, revenues or prospects, and increase the costs associated with conducting our business. The procurement and transplantation of allograft tissue is subject to federal regulation under the National Organ Transplant Act, or NOTA, a criminal statute that prohibits the purchase and sale of human organs, including bone and other tissue. NOTA permits the payment of reasonable expenses associated with the transportation, processing, preservation, quality control and storage of human tissue, which are the types of services we perform. If in the future, NOTA were amended or interpreted in a way that made us unable to include some of these costs in the amounts we charge our customers, it could reduce our revenues and therefore hurt our business. It is possible that more restrictive interpretations or expansions of NOTA could be adopted in the future which could require us to change one or more aspects of our business, at a substantial cost, in order to continue to comply with this statute.

Our success will depend on the continued acceptance of our allograft and xenograft implants and technologies by the medical community.

Market acceptance of our allograft and xenograft implants can be affected by factors such as competitive tissue repair options, lack of third party reimbursement and the training of surgeons in the use of our tissue transplants, and rapid technological changes such as synthetic hormone tissue substitutes.

Market acceptance depends on our ability to demonstrate that our existing and new implants and technologies are an alternative to existing tissue repair treatment options. This will depend on surgeons' evaluations of the clinical safety, efficacy, ease of use, reliability and cost-effectiveness of these tissue repair options and technologies.

We or our competitors may be exposed to product liability claims which could cause us to be liable for damages or cause investors to think we will be liable for similar claims in the future.

The development of allografts and technologies for human tissue repair and treatment entails an inherent risk of product liability claims, and substantial product liability claims may be asserted against us. We are a party to a number of legal proceedings related to product liability.

The implantation of donated cadaveric human tissue products creates the potential for transmissions of communicable disease. Although we comply with Federal and state regulations and guidelines intended to prevent communicable disease transmission, and our tissue suppliers are also required to comply with such regulations, there can be no assurances that: (i) our tissue suppliers will comply with such regulations intended to prevent communicable diseases transmissions; (ii) even if such compliance is achieved, that our products have not been or will not be associated with transmission of disease; or (iii) a patient otherwise infected with disease would not erroneously assert a claim that the use of our products resulted in disease transmission.

Table of Contents

We currently have \$5 million of product liability insurance to cover claims. This amount of insurance may not be adequate for current claims if we are not successful in our defenses, and furthermore, we may not have adequate insurance coverage for any future claims that arise. Moreover, insurance covering our business may not always be available in the future on commercially reasonable terms, if at all. If our insurance proves to be inadequate to pay a damage award, we may not have sufficient funds to do so, which would harm our financial condition and liquidity. In addition, successful product liability claims made against one of our competitors could cause claims to be made against us or expose us to a perception that we are vulnerable to similar claims. In addition, claims against us, regardless of their merit or potential outcome, may also hurt our ability to obtain surgeon endorsement of our allografts or to expand our business.

Negative publicity concerning the use of donated human tissue in medical procedures could reduce the demand for our products and negatively impact the supply of available donor tissue.

There has recently been negative publicity concerning the use and method of obtaining donated human tissue that is used in medical procedures. This type of negative publicity could reduce the demand for our products or negatively impact the willingness of families of potential donors to agree to donate tissue, or tissue banks to provide tissue to us. In such event, we might not be able to obtain adequate tissue to meet the needs of our customers. As a result, our relationships with our customers and our results of operations could be materially and adversely affected.

Our success depends on the scope of our intellectual property rights and not infringing the intellectual property rights of others.

Our ability to compete effectively with other companies is materially dependent upon the success of our patents and how effective we are in enforcing them and protecting our trade secrets. If we are not successful and steadfast, it is highly likely that our competitors will exploit our proprietary technologies and innovations and will compete more effectively against us. It is also highly likely that our competitors, who also have greater resources than we do, will challenge our intellectual property rights, and attempt to invalidate, circumvent or render unenforceable any of our patents or propriety rights that we currently own or are licensed to us.

Because of the competitive nature of the biotechnology industry, there can be no assurances that we will not be required to litigate the enforcement of our patents and other intellectual rights. Moreover, there can be no assurances that we will not have to defend our existing or proposed products or processes against third party claims of patent infringement and other intellectual property claims. However the litigation may arise, intellectual property litigation is always costly and ends up diverting our financial and management resources and damages our business.

We may need to secure additional financing to fund our long-term strategic plan.

We expect to continue to make investments in our business to support our distribution efforts and future programs and initiatives, which may deplete our available cash balances. We believe that our available cash, cash equivalents, available lines of credit and anticipated future cash flow from operations will be sufficient to meet our cash needs for the foreseeable future. Our future liquidity and capital requirements will depend upon numerous factors, including but not limited to, the progress of our product development programs and the need for and associated costs relating to regulatory approval, if any, which may be needed to commercialize some of our products under development, or those commercialized products whose regulatory status may change.

We may need to raise additional funds through the issuance of equity and/or debt financing in private placements or public offerings to provide funds to meet the needs of our long-term strategic plan. Additional funds may not be available, or if available, may not be available on favorable terms. Further equity financings, if obtained, may substantially dilute the interest of our pre-existing shareholders. Any additional debt financing

Table of Contents

may contain restrictive terms that limit our operating flexibility. As a result, any future financings could have a material adverse effect on our business, financial condition or results of operations.

THE OFFERING

This prospectus relates to the resale by Azimuth of up to 757,524 shares of our common stock as follows:

(a) Up to 582,524 shares of common stock which are issuable upon conversion of \$3,000,000 subordinated convertible debentures.

(b) Up to 175,000 shares of common stock to which are issuable upon exercise of warrants.

The Selling Stockholder may offer to sell the shares of common stock covered by this prospectus on the trading market of the American Stock Exchange or in private transactions or any other method permitted under applicable law. These sales may be at fixed or negotiated prices. We will not receive any proceeds from the resale of shares of our common stock by the Selling Stockholder.

USE OF PROCEEDS

The shares of common stock offered by this prospectus are being registered for the account of the Selling Stockholder named in this prospectus. As a result, all proceeds from the sales of the common stock will go to the Selling Stockholder and we will not receive any proceeds from the resale of the common shares by the Selling Stockholders. We will, however, receive proceeds from the exercise, if any, of the warrants held by Azimuth. All costs associated with this registration statement and prospectus will be incurred by us.

Table of Contents**MARKET FOR COMMON STOCK**

The Company's common stock is traded on AMEX, under the symbol TTG. The quotations set forth below reflect inter-dealer prices, without retail mark-up, markdown, or commission, and do not necessarily reflect actual transactions. Set forth below is the range high and low closing price information for the Company's common stock for the periods indicated.

	High	Low
Fiscal 2005		
Quarter Ended December 31, 2004	\$3.13	\$2.24
Quarter Ended March 31, 2005	\$2.60	\$2.30
Quarter Ended June 30, 2005	\$2.42	\$2.11
Quarter Ended September 30, 2005	\$4.56	\$2.35
Fiscal 2006		
Quarter Ended December 31, 2005	\$4.40	\$2.62
Quarter Ended March 31, 2006	\$5.00	\$2.92
Quarter Ended June 30, 2006	\$5.20	\$4.55
Quarter Ended September 30, 2006	\$6.24	\$4.21
Fiscal 2007		
Quarter (through December 21, 2006)	\$7.20	\$4.32

On December 21, 2006, the closing price of our common stock was \$7.15 per share.

As of November 30, 2006, there were approximately 714 stockholders of record of the Company's common stock. Our registrar and transfer agent is Computershare Investor Services, 7530 Lucerne Drive, Suite 100, Cleveland, Ohio 44130.

Dividends

We have not paid any cash dividends to date and do not anticipate or contemplate paying cash dividends in the foreseeable future. We currently intend to retain any future earnings to fund the development and growth of our business.

Table of Contents**SELECTED CONSOLIDATED FINANCIAL DATA**

The following table sets forth our selected consolidated statements of operations and balance sheets for the periods indicated and have been derived from our consolidated financial statements included elsewhere in this prospectus. The selected financial data is qualified by reference to and should be read in conjunction with Management's Discussion and Analysis of Financial Condition and Results of Operations and our consolidated financial statements and related notes included elsewhere in this prospectus.

	Year Ended September 30,				
	2002	2003	2004	2005	2006
	(Dollars in thousands, except per share data)				
Revenue	\$ 20,747	\$ 30,260	\$ 29,330	\$ 31,860	\$ 37,947
Cost of revenue	8,434	10,195	11,852	20,129	16,336
Gross profit	12,313	20,065	17,478	11,731	21,611
Operating expenses:					
General and administrative	3,287	4,482	4,151	5,790	7,803
Distribution and marketing	6,294	8,835	8,737	11,509	12,261
Research and development	886	826	1,432	1,659	1,834
Litigation		657	(406)		
Total operating expenses	10,467	14,800	13,914	18,958	21,898
Provisions for (benefit of) income taxes	778	1,137	1,306	(436)	(194)
Net income (loss)	901	3,707	1,133	(7,017)	(589)
Comprehensive income (loss) :					
Foreign currency translation gain (loss)	253	1,006	2,167	(570)	715
Comprehensive income (loss)	1,154	4,713	3,300	(7,587)	126
Average shares outstanding for basic earnings (loss) per share	15,114,412	15,495,148	15,734,470	15,919,286	16,027,469
Basic earnings (loss) per share	0.06	0.24	0.07	(0.44)	(.04)
Average shares outstanding for diluted earnings (loss) per share	15,959,975	16,095,448	16,469,443	15,919,286	16,027,469
Diluted earnings (loss) per share	0.06	0.23	0.07	(0.44)	(.04)

	2002	2003	September 30, 2004	2005	2006
Balance Sheet Data:					
Working capital	\$10,856	\$15,342	\$17,471	\$ 8,433	\$ 8,215
Total assets	23,748	29,962	33,536	26,205	38,917
Long-term debt	693	728	827	814	4,770
Stockholders equity	13,928	17,606	21,272	13,722	15,221

Table of Contents

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS**

You should read the following discussion together with Selected Consolidated Financial Data and our consolidated financial statements and the related notes included elsewhere in this prospectus. This discussion contains forward-looking statements about our business and operations, based on current expectations and related to future events and our future financial performance, that involve risks and uncertainties. Our actual results may differ materially from those we currently anticipate as a result of many important factors, including the factors we described under Risk Factors, and Forward-Looking Statements elsewhere in this prospectus.

General Background

Tutogen Medical, Inc., a Florida corporation, was formed in 1985 and with its consolidated subsidiaries (collectively, the Company or Tutogen), designs, develops, processes, manufactures and markets sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Surgeons use our products to repair and promote the healing of a wide variety of bone and other tissue defects, including dental, spinal, urology, ophthalmology, head, neck and general surgery procedures. Our products are distributed throughout the United States and in over twenty (20) other countries.

We pursue a market approach to the distribution of our implants and establish strategic distribution arrangements in order to increase our penetration in selected markets. We have distribution agreements with Zimmer Dental and Zimmer Spine for the dental and spine markets, Mentor, Inc. for breast reconstruction, IOP, Inc. for ophthalmology, Davol for hernia, Coloplast for urology and Sense Medical for ears, nose and throat. In all other markets that we serve, we use a network of independent distributors.

Critical Accounting Policies

The Company's significant accounting policies are more fully described in Note 2 to the consolidated financial statements. However, certain of the accounting policies are particularly important to the portrayal of the financial position and results of operations and require the application of significant judgment by management; as a result, they are subject to an inherent degree of uncertainty. In applying those policies, management uses its judgment to determine the appropriate assumptions to be used in the determination of certain estimates. Those estimates are based on historical experience, terms of existing contracts, observance of trends in the industry, information provided by customers and information available from other outside sources, as appropriate. The Company's significant accounting policies include:

Share-Based Compensation

We adopted Statement of Financial Accounting Standards No. 123R, SHARE-BASED PAYMENTS in the first quarter of fiscal year 2006. SFAS 123R requires the measurement and recognition of compensation expense for all share-based payment awards including employee stock options based on estimated fair values. Under SFAS 123R, we estimate the value of share-based payments on the date of grant using the Black-Scholes model, which was also used previously for the purpose of providing pro forma financial information as required under SFAS 123. The determination of the fair value of, and the timing of expense relating to, share-based payment awards on the date of grant using the Black-Scholes model is affected by our stock price as well as assumptions regarding a number of variables including the expected term of awards, expected stock price volatility and expected forfeitures.

Prior to the first quarter of fiscal year 2006, we used historical stock price volatility in preparing our pro forma information under SFAS 123. Under SFAS 123R, we use a combination of historical and implied volatility to establish the expected volatility assumption based upon our assessment that such information is

Table of Contents

more reflective of current market conditions and a better indicator of expected future volatility. SFAS 123R also requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. We estimate expected forfeitures, as well as the expected term of awards, based on historical experience. Future changes in these assumptions, our stock price or certain other factors could result in changes in our share-based compensation expense in future periods.

Inventories

Inventories are valued at the lower of cost or market. Work in process and finished goods includes costs attributable to direct labor and overhead. Impairment charges for slow moving, excess and obsolete inventories are recorded based on historical experience, current product demand including meeting periodically with distributors, regulatory considerations, industry trends, changes and risks and the remaining shelf life. As a result of this analysis, the Company records an allowance to reduce the carrying value of any impaired inventory to its fair value, which becomes its new cost basis. If the actual product life cycles, demand or general market conditions are less favorable than those projected by management, additional inventory impairment charges may be required which would affect future operating results due to increases costs from the resulting adjustment. The adequacy of these impairment charges is evaluated quarterly.

Revenue Recognition and Accounts Receivable

Revenue on product sales is recognized when persuasive evidence of an arrangement exists, the price is fixed and final, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Oral or written purchase authorizations are generally obtained from customers for a specified amount of product at a specified price. Title transfers at the time of shipment. Customers are provided with a limited right of return. Revenue is recognized at shipment. Reasonable and reliable estimates of product returns are made in accordance with the Financial Accounting Standards Board Statement of Financial Accounting Standard (SFAS) No. 48 and allowances for doubtful accounts are based on significant historical experience. Revenue from distribution fees includes nonrefundable payments received as a result of exclusive distribution agreements between the Company and independent distributors. Distribution fees under these arrangements are recognized as revenue ratably to approximate services provided under the contract. Recognition of revenues commenced over the term of the distribution agreement upon delivery of initial products.

Valuation of Deferred Tax Asset

We record valuation allowances to reduce the deferred tax assets to the amounts estimated to be recognized. While we consider taxable income in assessing the need for a valuation allowance, in the event we determine it is more likely than not we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance would be made and income increased in the period of such determination. Likewise, in the event we determine we would not be able to realize all or part of our deferred tax assets in the future, an adjustment would be made to the valuation allowance and charged to income in the period of such determination. We recorded a deferred tax asset valuation allowance of \$6.1 million and \$6.3 million at September 30, 2006 and 2005, respectively; representing 100% of existing U.S. net deferred tax assets.

Table of Contents**Year Ended September 30, 2006 Compared to Year Ended September 30, 2005 Results of Operations Revenue and Gross Margin**

Revenue for the year ended September 30, 2006 increased to \$37.9 million from \$31.9 million in 2005. The U.S. revenues were \$25.4 million or 17% higher than the 2005 revenues of \$21.8 million. The increase in U.S. revenues was fueled by the continuing increase in the demand for the Company's *Tutopla*® bone products for dental applications sold by Zimmer Dental, the company's distributor. In February 2006, the Company developed, in association with Zimmer Dental, a new pericardium product, and in September 2006, a new dermis product to augment ridge restoration. Sales of dental products increased 28% from a year ago. Spine revenues decreased 9% as the Company transitions from traditional spine grafts to specialty machined grafts. The Company introduced two new machined grafts, Puros C and Puros A during the fourth quarter of fiscal year 2006. Surgical specialties (primarily urology, ophthalmology and ENT) remained flat for 2006 compared to 2005.

The International operation had revenues of \$12.5 million for the year ended September 30, 2006, an increase of 24% from the 2005 revenues of \$10.1 million. The increase is primarily due to additional sales in Germany related to increased bovine product sales, dental sales and service processing and increased sales efforts by several key distributors in various countries.

Gross margins for the year ended September 30, 2006 increased to 57% from 37% in 2005. The higher margins were due to (1) improved efficiencies in the U.S. manufacturing operations; and (2) the introduction of new products with higher margins. In addition, during fiscal year 2005, the gross margin was impacted by initial start-up manufacturing costs of \$1.6 million associated with shifting production of the dental product lines from Germany to the U.S. and the recording of \$1.25 million in expenses due to inventory write-down and certain accruals associated with the voluntary recall of products.

General and Administrative

General and administrative expenses increased in 2006 to \$7.8 million from \$5.8 million in 2005. The increase was due to several charges including \$437,000 in severance costs associated with the replacement of the Managing Director of the Company's German subsidiary, \$217,000 in legal, accounting and other professional costs associated with the restatement of prior period financial results and \$262,000 related to strategic discussions with Zimmer Holdings. The Company incurred, for the first time, \$451,000 in stock option expenses associated with the adoption of Statement of Financial Accounting Standards No. 123R. In addition, the Company incurred increased legal expenses of approximately \$250,000 and accounting and audit fees of approximately \$200,000 for various projects during the year. As a result, General and Administrative expenses, as a percentage of revenues, increased from 18% in 2005 to 20% in 2006.

Distribution and Marketing

Distribution and Marketing expenses increased in 2006 to \$12.3 million from \$11.5 million in 2005. The increase was due mainly to higher marketing fees paid to Zimmer Dental of \$7.2 million in 2006 versus \$6.1 million a year ago as dental revenues increased to \$17.6 million in 2006 up from \$13.8 million in 2005. As a percentage of revenues, Distribution and Marketing expenses decreased from 36% in 2005 to 33% in 2006.

Research and Development

Research and Development expenses of \$1.8 million were similar in 2006 to \$1.7 million in 2005. As a percentage of revenues, Research and Development expenses remained at 5% in 2006 and 2005, respectively.

Table of Contents

Litigation Contingency

In 2004, a decision by the court of appeal in Germany has resulted in a reduction of the original proposed judgment received against the Company by \$406,000 between the Company and a former international distributor. At September 30, 2005, the Company maintained an accrual of \$476,000 with respect to the remaining appeal and legal costs. At September 30, 2006, the Company agreed to a settlement of \$360,000 resulting from a dispute between the Company and a former international distributor and recorded a change in estimate of approximately \$91,000 as a reduction of accrued expenses, which reduced the general and administrative expense for the year. The remaining accrual will be used to settle final nominal legal and court costs.

Other Income

Other income for 2006 increased to \$108,000 compared to \$77,000 in 2005. This was primarily the result of higher interest income on bank balances in 2006.

Interest Expense

Interest expense in 2006 increased to \$293,000 from \$130,000 in 2005 due to increased borrowings for capital expenditures related to the facility expansion programs in Florida and Germany and interest expense associated with a \$3.0 million convertible debenture issued in June 2006.

Income Tax (Benefit) Expense

The income tax benefit is mainly due to the income tax benefit on the loss from the Company's foreign operations. The Company continues to record a full valuation allowance on its U.S. operations.

Net (Loss) Income

The net loss for the year ended September 30, 2006 totaled \$.6 million, \$.04 basic and diluted loss per share as compared to a net loss of \$7 million or \$.44 basic and diluted loss per share for 2005. The reduction in net losses between the years is directly attributable to higher revenues and improved gross margins during 2006.

Accounts Receivable

The accounts receivable balance increased in 2006 to \$6.2 million, up from \$3.5 million in 2005 due to increased revenue growth, particularly during the fourth quarter of 2006. In addition, for certain international distributors, payment terms have been extended from 60 to 90 days contributing to higher receivable balances in 2006.

Inventory

The inventory balance increased to \$12.7 million at September 30, 2006 from \$9.6 million at September 30, 2005. The increase was primarily due to replacing \$1.0 million of inventory written-off during 2005 due to the voluntary recall of certain products, and increased inventories associated with the recent introduction of new products.

Foreign Currency Translation

The functional currency of the Company's German subsidiary is the Euro. Assets and liabilities of foreign subsidiaries are translated at the period end exchange rate while revenues and expenses are translated at the average exchange rate for the period. The resulting translation adjustments, representing unrealized, non-

Table of Contents

cash gains and losses are made directly to comprehensive income. Gains and losses resulting from transactions between the Company and its subsidiaries, which are made in currencies different from their own, are included in income as they occur and are included in Foreign exchange loss in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. The Company recognized transaction losses of \$311,000, \$173,000 and \$700,000 in 2006, 2005 and 2004, respectively.

Effects of Inflation

The Company believes the impact of inflation and changing prices on net sales revenues and on operations has been minimal during the past three years.

Year Ended September 30, 2005 Compared to Year Ended September 30, 2004 Results of Operations**Revenue and Gross Margin**

Revenue for the year ended September 30, 2005 increased \$2.6 million or 9% to \$31.9 million from \$29.3 million in 2004. The U.S. revenues were \$21.8 million or 27% higher than the 2004 revenues of \$17.1 million. The increase in U.S. revenues was fueled by the continuing increase in the demand for the company's *Tutopla*[®] bone products for dental applications sold by Zimmer Dental (Dental), the Company's marketing distributor. In January 2005, the Company developed, in association with Zimmer Dental, a new bone block to augment ridge restoration. The Dental business increased 100% from a year ago. The spine revenues decreased 36%, primarily due to significant purchases by Zimmer Spine in 2004. The urology business was essentially flat with a decrease of 6% from a year ago as this business is decreasing due to the increased reliance on synthetics for incontinence. However, Mentor continues to do well in the pelvic floor reconstruction market, with a slight increase in revenues for this product line. The ophthalmic business was essentially flat as this is a mature and niche business.

The international operation had revenues of \$10.1 million for the year ended September 30, 2005, a decrease of \$2.1 million or 17% from the 2004 revenues of \$12.2 million. The decrease in revenues was primarily due to the temporary delay in the renewal of the CE marks (European Conformity) on certain products, which was resolved at the end of the first quarter of 2005, the resolution of certain regulatory issues in France and the temporary backlog of xenograft product lines.

Gross margins for the year ended September 30, 2005 decreased to 37% from 60% in 2004. The lower margins were due to several factors, (1), an unfavorable mix of lower margin products from the dental product revenues versus the spine revenues. (Dental revenues as a percentage of total revenues increased to 43% of total revenues versus 24% a year ago), (2), initial start-up manufacturing costs of \$1.6 million, expensed in the third quarter, associated with shifting production of the dental product lines from Germany to the U.S. (the production transfer has been fully completed), (3), the recording in the fourth quarter of \$1.0 million for the inventory reserve impact of the voluntary recall of products during fiscal year 2005, (4), the estimated patient testing and other related expenses of \$250,000 as a result of the product recall recorded in the fourth quarter of fiscal year 2005.

Voluntary Recall

On October 12, 2005, the Company issued a voluntary recall of all product units which utilized donor tissue received from BioMedical Tissue Services/BioTissue Recovery Services (BioMedical). This action was taken because the Company was unable to satisfactorily confirm that BioMedical had properly obtained donor consent. The Company quarantined all BioMedical products in its inventory, having a value of \$1,035,000 and has notified all customers and distributors of record regarding this action. In connection with this recall, the Company wrote off \$1,035,000 of inventory and accrued \$250,000 of other related costs during the year ended September 30, 2005.

Table of Contents**General and Administrative**

General and administrative expenses increased 38% in 2005 to \$5.8 million from \$4.2 million in 2004. The increase was due to higher compensation costs related to new personnel (\$534,000), expenses related to the closing of the New Jersey Corporate Offices (\$444,000), expenses related to Sarbanes-Oxley compliance (\$118,000), unfavorable translation of Euro-based expenses (\$84,000), and other expenses (\$26,000). As a result, General and Administrative expenses, as a percentage of revenues, increased from 14% in 2004 to 18% in 2005.

Distribution and Marketing

Distribution and Marketing expenses increased 32% or \$2.8 million in 2005 to \$11.5 million from \$8.7 million in 2004. The increase was due mainly to higher marketing fees paid to Zimmer Dental of \$6.1 million in 2005 versus \$3.2 million a year ago or an increase of \$2.9 million. This is a result of a 100% increase in dental revenues in 2005, from \$6.9 million of revenues in 2004 to \$13.8 million in 2005. As a result, Distribution and Marketing expenses, as a percentage of revenues, increased from 30% in 2004 to 36% in 2005.

Research and Development

Research and Development expenses increased 16% or \$0.3 million in 2005 to \$1.7 million. The increase was due to increased development efforts in the dental and spine product areas. As a percentage of revenues, Research and Development expenses remained at 5% in 2005 and 2004.

Litigation Contingency

In 2004, a decision by the court of appeal in Germany resulted in a reduction of the original proposed judgment received against the Company by \$406,000 between the Company and a former international distributor. At September 30, 2005 and 2004, the Company maintained an accrual of \$476,000 with respect to the remaining appeal and legal costs.

Other Income/Expense

Other income/expense for 2005 decreased \$505,000 from \$601,000 in 2004 to \$96,000 in 2005. This was primarily the result of lower foreign exchange losses due to the strengthening of the dollar versus the Euro and lower inter-company balances at year-end.

Interest Expense

Interest expense in 2005 increased due to borrowings for capital expenditure equipment related to the facility expansion programs in Florida and Germany.

Income Tax (Benefit) Expense

Income Tax (Benefit) Expense is mainly due to the income tax benefit on the loss from the Company's foreign operations. The Company continues to record a full valuation allowance on its U.S. operations.

Net (Loss) Income

As a result of the above, net loss for the year ended September 30, 2005 totaled \$7.0 million, \$0.44 basic and diluted loss per share as compared to a net income of \$1.1 million, \$0.07 basic and diluted earnings per share for 2004. As a percentage of revenues, net income decreased from 3.9% in 2004 to a net loss of twenty-two percent (22%) in 2005.

Table of Contents

Concentration of Risk

Distribution

The majority of the Company's revenues are derived through the Company's relationships with two companies, Zimmer Dental and Zimmer Spine which contributed approximately 46% and 8%, respectively, of the Company's consolidated revenues during 2006. If the Company's relationship with such companies is terminated or further reduced for any reason and we are unable to replace the relationship with other means of distribution, the Company would suffer a material decrease in revenues.

Tissue Supply

The Company's business is dependent on the availability of donated human cadaver tissues supplied by donor recovery groups. Allosource, our largest donor recovery group, supplied the Company with approximately 65% of our total human tissue for the year ended September 30, 2006. Our three largest recovery groups together supplied approximately 83% of our total human tissue during 2006. Any significant interruption in the availability of human tissue would likely cause the Company to slow down the processing and distribution of the Company's human tissue products, which could adversely affect the Company's ability to supply the needs of the Company's customers and materially and adversely affect the results of operations and the relationships with customers.

Trade Receivables

As of September 30, 2006, one customer, Zimmer Spine, represented 15% of the Company's outstanding trade receivables. No other customer represented more than 10% of the Company's outstanding trade receivables.

Foreign Currency

The exposure to risk related to foreign currency exchange is limited primarily to inter-company transactions. At September 30, 2006 the Company substantially reduced its foreign currency exposure through the elimination of certain intercompany accounts.

Liquidity and Capital Resources

At September 30, 2006 and 2005 the Company had working capital of \$8.2 million and \$8.4 million, respectively.

Cash and cash equivalents remained consistent from \$3.6 million in 2005 to \$3.5 million in 2006.

Net cash used in investing activities, representing purchases of capital expenditures, was \$6 million in 2006 and \$1.7 million in 2005. The continued spending on capital expenditures is due to the facility expansion in the Florida and German manufacturing locations and manufacturing equipment.

Net cash from financing activities in 2006 and 2005 totaled \$7.9 million and \$1.0 million, respectively, from proceeds related to revolving credit facilities, a \$3.0 million convertible debenture, additional long-term debt and capital leases.

Under the terms of revolving credit facilities with two German banks, the Company may borrow up to 1.5 million Euros (1 million Euros and .5 million Euros, respectively) or approximately \$1.9 million for working capital needs. These renewable credit lines allow the Company to borrow at interest rates ranging from 8.05% to 9.5%. At September 30, 2006 the Company had outstanding borrowings of 819,000 Euros or \$1

Table of Contents

million. At September 30, 2005, the Company had no borrowings under the revolving credit agreements. The .5 million Euro revolving credit facility is secured by accounts receivable of the German subsidiary. The 1 million Euro revolving credit facility is secured by a mortgage on the Company's German facility and a guarantee by the parent Company.

In November 2005, the Company entered into a revolving credit facility in the U.S. for up to \$1.5 million, expiring on November 18, 2007. At September 30, 2006, the Company had outstanding \$1.5 million on this credit facility to fund working capital needs. The U.S. accounts receivable and inventory assets secure the borrowing under the revolving credit facility. The Company is required to maintain a maximum senior debt to tangible net worth ratio of 2.0 to 1.0. As of September 30, 2006, the Company was in compliance with this covenant.

On June 30, 2006, the Company issued a \$3 million convertible debenture with detachable warrants to purchase up to 175,000 shares of its common stock. The debenture bears interest at 5.0% per year, is due upon the earlier of 12 months or upon a change of control of the Company and is convertible into common stock at a price of \$5.15 per share at any time at the election of the holder. The warrants are exercisable at \$5.15 per share at any time at the election of the shareholder until the earlier of the third anniversary of the date of issuance or upon a change in control of the Company. The convertible debt is included in Short-term borrowings on the consolidated balance sheet at September 30, 2006. As of September 30, 2006, the Company was in compliance with the terms and conditions of the convertible debenture.

Senior debt consists of two loans with a German bank. The first loan (\$576,000 as of September 30, 2006) has an interest rate of 5.75%, payable monthly, maturing March of 2011. The second loan (\$1,744,000 as of September 30, 2006) has an interest rate of 5.15%, payable quarterly, maturing March of 2012.

The Senior debt, refinanced construction line of credit, and a revolving credit facility with a German bank are secured by a mortgage on the Company's German facility and is guaranteed by the parent company. There are no financial covenants under this debt.

The Company has an interim loan of 1 million Euros or approximately \$1.3 million, at an annual interest rate of 5.75%, to finance its facility expansion project in Germany. The interim loan was converted to a long-term loan November 30, 2006. This loan has a 10 year term, payable semi-annually (55,000 Euros) at a fixed rate of 5.6%.

The Capital lease debt consists of two leases. The first lease (initially \$1.3 million, \$1.1 million as of September 30, 2006) is payable monthly at \$55,000 per month and matures April of 2008. The lease is secured by leasehold improvements and equipment located at the Company's Florida tissue processing facility. The second lease (initially \$224,000 and \$85,000 as of September 30, 2006) is payable at \$22,000 quarterly and matures September of 2007. The lease is secured by equipment located at the Company's Florida tissue processing facility. As of September 30, 2006, the Company is in compliance with the terms and conditions of the Capital lease debt.

The Company's future minimum commitments and obligations under current operating leases for its offices and manufacturing facilities in the U.S. and Germany, as well as several leases related to office equipment and automobiles through 2010 total \$2,111,000 million. The Company considers these commitments and obligations to be reasonable in order to maintain the current and future business requirements.

Table of Contents

The following table summarizes the Company's contractual obligations as of September 30, 2006:

	Total	2007	2008	2009	2010	2011	2012
	(In thousands)						
Long Term debt (1)	\$ 4,770	\$ 1,097	\$ 1,033	\$ 533	\$ 545	\$ 482	\$ 1,080
Operating Lease obligations	\$ 2,111	\$ 988	\$ 748	\$ 343	\$ 32	\$ 0	\$ 0
Short-term borrowings (1)	\$ 5,783	\$ 5,783	\$ 0	\$ 0	\$ 0	\$ 0	\$ 0
	\$ 12,664	\$ 7,868	\$ 1,781	\$ 876	\$ 577	\$ 482	\$ 1,080

(1) Does not include interest

The Company maintains current working capital credit lines totaling 1.5 million Euros (approximately \$1.9 million) with two German banks and a \$1.5 million credit line with a U.S. bank. At September 30, 2006 the Company had outstanding balances of \$1.0 million and \$1.5 million for the working capital lines in Germany and the U.S., respectively. Management believes that the working capital as of September 30, 2006, together with the revolving lines of credit, will be adequate to fund ongoing operations. While the Company believes that it continues to make progress in these areas, there can be no assurances that changing governmental regulations will not have a material adverse effect on results of operations or cash flow. The Company may seek additional financing to meet the needs of its long-term strategic plan. The Company can provide no assurance that such additional financing will be available, or if available, that such funds will be available on favorable terms. The Company's ability to generate positive operational cash flow is dependent upon increasing processing revenue through increased recoveries by tissue banks in the U.S. and Europe, controlling costs, and the development of additional markets and surgical applications for its products worldwide.

Off Balance Sheet Arrangement

Guarantees In October 2005, the Parent Company agreed to provide a guarantee up to 4 million Euros for the Company's German subsidiary's debt to a German bank. At September 30, 2006, total debt outstanding to the German bank was 3.2 million Euros. The Company has no other off-balance sheet arrangements.

DESCRIPTION OF BUSINESS

Tutogen Medical, Inc., a Florida corporation, was formed in 1985, and with its consolidated subsidiaries (collectively, the Company or Tutogen), develops, manufactures and markets sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Surgeons use our products to repair and promote the healing of a wide variety of bone and other tissue defects, including dental, spinal, urology, ophthalmology, head, neck and general surgery procedures. Our products are distributed throughout the United States and in over twenty (20) other countries.

The Company contracts with independent tissue banks and procurement organizations to provide donated human tissue for processing using the Company's proprietary *Tutoplast*® process. The *Tutoplast*® process utilizes solvent dehydration and chemical inactivation which is applied to two types of preserved allografts: soft tissue; consisting of fascia lata, fascia temporalis, pericardium, dermis, and sclera, and bone tissue; consisting of various configurations of cancellous and cortical bone material. Processed pericardium, fascia lata and dermis are collagenous tissue used to repair, replace or line native connective tissue primarily in dental, ophthalmology, urology, plastic and reconstructive surgeries. Dermis is also used in hernia repair and pelvic floor reconstruction. Sclera is used in ophthalmology procedures such as, anterior and posterior segment patch grafting applications for glaucoma, retina and trauma surgery and oculoplastics, as well as contour wrapping of an orbital implant. Processed cortical and cancellous bone material is used in a wide variety of applications in spinal, orthopaedic and dental surgeries. All processed tissues have a shelf life of five (5) years, at room temperature, and require minimal time for rehydration.

Table of Contents

In contrast to other processors using freeze-drying, deep freezing or cryopreservation for human tissues, the *Tutoplast*® process utilizes a technique in which tissues are soaked and washed in a series of aqueous solutions and organic solvents, removing water and substances that could cause rejection or allergic reaction. This technique dehydrates the tissue, while maintaining its structure and allowing it to act as a scaffold after implantation, which is subsequently replaced by newly formed autologous tissue. During processing, the tissues are treated with agents shown to inactivate viruses such as hepatitis and HIV (the virus responsible for AIDS), rendering the allografts safe for the recipient. Soft tissue is also treated with chemicals shown to be effective against prions, the agent causing Creutzfeldt-Jakob Disease (CJD). Once packaged, tissues are terminally sterilized by low dosage gamma radiation.

An analysis of our revenues is as follow:

	Year Ended September 30,		
	2004	2005	2006
	(In thousands)		
Dental	\$ 6,893	\$ 13,785	\$ 17,616
Spine	4,850	3,128	2,877
Surgical Specialties	5,383	4,839	4,937
Total U.S.	\$ 17,126	\$ 21,752	\$ 25,430
Germany	\$ 3,521	\$ 1,980	\$ 2,851
Rest of World (ROW)	6,001	6,220	7,472
France	2,121	1,337	1,672
Other Distribution Fees	561	571	522
Total International	\$ 12,204	\$ 10,108	\$ 12,517
Total Consolidated	\$ 29,330	\$ 31,860	\$ 37,947

Manufacturing and Processing

Tutogen considers itself a leader in the manufacturing and marketing of human allograft and animal xenograft tissue implant products, which significantly improve surgical outcomes for the medical professional and quality of life for patient recipients. We believe our proprietary *Tutoplast*® tissue preservation and sterilization process has the greatest longevity of any similar methodology in the industry today. In use for more than thirty (30) years, there have been well over one and one-half million (1,500,000) Tutogen products implanted without a single documented case of disease transmission.

Donated bone and soft tissues are received and quarantined by Tutogen Quality Control (QC) until release by the Quality Assurance (QA) department and Tutogen's Medical Director, a licensed physician. In the interim, tissues are stored in a controlled environment, limited-access area according to requirements set forth by the American Association of Tissue Banks (AATB). Each tissue is given a unique identification number in order to maintain full traceability. Once released for processing, tissues are transferred to manufacturing and kept in a refrigerated or frozen state until issued to a specific production work order.

Following assignment to a manufacturing work order, tissue materials go through appropriate preprocessing operations and into the multi-stage *Tutoplast*® process. This process removes blood, lipids and extraneous materials, inactivates viruses and prions, and breaks down RNA and DNA into fragments not capable of replication and disease transmission while preserving the biological and mechanical properties. The *Tutoplast*® process yields a dehydrated, semi-processed product that may be stored at room temperature for

Table of Contents

extended periods of time. This tissue is subsequently processed to size and/or shape and packaged for terminal sterilization. All Tutogen packaged products are subjected to low dose gamma irradiation, which further enhances tissue safety and eliminates ancillary contamination that may be present from pre-sterilization handling. This terminal sterilization is performed by a third-party contractor utilizing a validated cycle.

While some of the *Tutoplast*® processing steps are automated, the majority are manual and rely on highly-skilled personnel for their proper execution. Such skilled labor is readily available in the surrounding geographic areas and management feels that there should be no adverse affect on the business related to the labor market.

Tutogen operates two tissue processing facilities; a 26,000 square foot facility in Alachua, Florida and a 33,000 square foot facility in Neunkirchen, Germany. Major expansion projects were recently completed at both facilities, and will be in service by the first calendar quarter of 2007. These expansion projects are intended to ensure the availability of sufficient production capacity to address the increasing demand for the Company's allograft and xenograft products in the foreseeable future. The Alachua, Florida facility is a U.S. Food and Drug Administration registered medical device and biological establishment and is accredited by and a member of the American Association of Tissue Banks. The Neunkirchen, Germany facility is certified according to ISO9001 and EN4600, and is registered as a biological establishment with the U.S. Food and Drug Administration

Quality Assurance and Regulatory Affairs

The Company maintains comprehensive quality assurance and regulatory compliance programs that provide oversight for all pertinent aspects of the Company's day-to-day operational activities. Among the responsibilities of the QA/RA organizations are:

- Maintenance of an extensive documentation and change-control system (specifications, standard operating procedures and engineering drawings)

- Internal and external auditing for compliance with international and domestic regulatory body or accrediting organization regulations or requirements

- Review and approval of donor medical record information and screening/test documentation

- Product and process document review and release for distribution

- Evaluation and follow-up of all Tutogen-related product complaints

- Management of Corrective and Preventive Action programs to reduce or eliminate any identified non-conformances

The Quality Assurance and Regulatory Affairs departments are independent from the manufacturing operation, functioning under the supervision of the Tissue Bank Director (a medical doctor) and senior management staff.

Marketing and Distribution

Tutogen's products and processing services are provided globally through a combination of worldwide distributors, direct representatives and local distributors. Tutogen's personnel, along with distributors and their representatives, conduct product training sessions, make joint customer calls, set objectives and evaluate their representatives performance. Personnel also call on select physicians and key hospital accounts in order to provide needed clinical and technical information services. The overall strategy is to work with each global

Table of Contents

distributor to expand penetration into currently covered regions, develop additional global opportunities, and to broaden the product portfolio with procedure-specific products. In markets not covered by its global distributors, Tutogen's focus is on adding local distributors or direct operations capable of market penetration.

Approximately 70% of the Company's revenues are derived within the United States while the remaining international sales are derived primarily from Europe. Since Tutogen's foreign donor procurement practices are in full compliance with the donor suitability standards of the AATB and the U.S. Food and Drug Administration (FDA), the Company has worked closely with its distributors to expand into numerous market opportunities world wide. Tissue grafts are used in dental, spine, urology, ophthalmology, hernia, general surgery, head and neck applications, and plastic and reconstructive surgeries. Future objectives are to match this penetration into additional international and specialty markets, using either *Tutoplast*® processed human allograft or xenograft tissue implants.

The Company's U.S. marketing efforts have concentrated on building a marketing and distribution organization, capable of supporting its various distributors. The Company has entered into several exclusive marketing and distribution agreements with global medical device companies. These agreements have established exclusive distribution for *Tutoplast*® processed implants in specialized indications and surgical applications, for select international markets.

Zimmer Dental and Zimmer Spine, subsidiaries of Zimmer Holdings, provide marketing services for the Company's products for the dental and spine markets. Starting in September 2000, Zimmer Dental entered into an agreement to represent *Tutoplast*® processed bone, under the brand name Puros®, for dental applications. Revenues from this relationship account for 46% of total consolidated and 69% of total U.S. revenues for the fiscal year ended September 30, 2006. Zimmer Dental represents the products to the end user and the Company ships and bills the customer directly. Distribution fees earned pursuant to the agreements are recognized ratably over the terms of these respective agreements. During 2006, the Company expanded its relationship with Zimmer Dental by adding pericardium and dermis soft tissue grafts for dental applications. The additions of these new products provide Zimmer Dental with a full line of products for the dental surgeons. During 2006, the Company extended Zimmer Dental's exclusivity into select international markets.

Also starting September 2000, Zimmer Spine began representing Tutogen bone products for applications in the spine market. Initially, Tutogen shipped and billed the customers directly, but in April 2003 the Company entered into an exclusive license and distribution agreement with Zimmer Spine. Effective with this agreement Zimmer Spine became a stocking distributor, therefore Zimmer Spine now purchases the Company's products and distributes and invoices the customer directly. Zimmer Spine distributes both traditional bone and specialized bone products processed with the Company's *Tutoplast*® process. Revenues from Zimmer Spine for 2006 represented 8% and 11%, of total consolidated and U.S. revenues, respectively.

The Company also manufactures products for surgical specialties which include urology, ophthalmology, ENT, hernia and aesthetics products. During 2006, sales from surgical specialties totaled 13% of consolidated revenue and 19% of US revenues.

For urological indications, the Company had partnered with Mentor Corporation (Mentor) since 1998. During 2006, Mentor sold their urology business to Coloplast A/S of Denmark (Coloplast), and assigned the Tutogen agreement to Coloplast. As a stocking distributor, Coloplast currently markets *Tutoplast*® fascia lata, pericardium, and dermis tissue implants. In April 2006, Tutogen and Mentor signed an agreement that extended the current contracts for one year to provide enough time for Mentor to consummate the sale of the urology business to Coloplast. The transition to Coloplast is ongoing, and a new definitive agreement with Coloplast is in discussion.

IOP, Inc. (IOP) has been a distributor since 1998, and is the exclusive distributor for *Tutoplast*® processed tissue for ophthalmology applications. Sense Medical, a distributor since December 2004, has non-

Table of Contents

exclusive rights to distribute *Tutoplast*® products for selected head and neck procedures.

In January 2006, the Company entered in to a four-year exclusive worldwide distribution agreement with Davol, Inc. (Davol), a subsidiary of C. R. Bard, Inc., to promote, market and distribute the Company's line of allograft biologic tissues for hernia repair and the reconstruction of the chest and abdominal walls. Under the agreement, Davol paid the Company \$3.3 million in fees for the exclusive distribution rights. Davol is a stocking distributor, and entered the hernia market during the fourth quarter of fiscal year 2006.

In June 2006, the Company signed a new exclusive distribution agreement with Mentor Corporation (Mentor) for the exclusive North American rights for the use of *Tutoplast*® dermis in the dermatology and plastic surgery markets for breast reconstruction. The Company received an upfront payment in consideration for these distribution rights. Shipments to Mentor, and market release will occur during fiscal year 2007.

Internationally, the Company concentrates on an in-depth penetration of markets with major needs not covered by Tutogen's global distributors. In Europe, the specific focus is on countries such as Germany, France, Italy, Spain and the U.K., and in major specialty areas, such as dental, orthopedics and tissue processing. Approximately 40% of the total international sales are xenograft products. The Company believes that through a combination of international distribution strategies, Tutogen can increase its penetration of the international markets for processed tissue.

The following table summarizes the Company's markets, products, applications and distributor:

Distributor	Market	Estimated Market Size U.S.	Products	Applications
Zimmer Dental	Dental	\$169.0 million	Puros Cancellous Puros Cortical Puros Block Puros Pericardium Puros Dermis	Ridge Augmentation
Zimmer Spine	Spine	\$656.0 million	Puros bone Specialty Machined Grafts (Puros C & Puros A)	Interbody Fusion Cervical and Lumbar
Davol	Hernia	\$150.0 million	AlloMax (Human Dermis Product)	Hernia Repair Reconstruction of the chest and abdominal walls
Coloplast	Urology	\$200.0 million	Suspend fascia lata Axis dermis Pericardium	Urinary Incontinence Pelvic Floor Reconstruction
Mentor	Breast Reconstruction	\$25.0 \$50.0 million	NeoForm dermis	Breast Reconstruction
IOP	Ophthalmology	\$9.0 million	IO Patch BioDome BioElevation BioSpacer	Glaucoma Enucleation Brow Suspension
	ENT	\$55.0 million		

Sense
Medical

Fascia lata
Fascia temporalis
Pericardium

Tympanoplasty
Rhinoplasty
Septoplasty

24

Table of Contents**Tissue Procurement**

The Company sources donor tissues from multiple independent recovery organizations in Europe and the United States. Recovery agencies obtain donor consent, verify proper donor identity, conduct extensive medical and social history evaluations and recover appropriate donated tissues. Each donor tissue is assigned a unique identification number in order to assure full traceability, from recovery to recipient. These records accompany each donor tissue receipt, along with related serological test samples. The test samples are evaluated by independent Clinical Laboratory Improvement Amendment (CLIA) certified laboratories for such transmissible diseases as Hepatitis B surface Antigen (HBsAg), Hepatitis B total core (HBc, IgG/IgM), Hepatitis C virus antibody (HCV Ab), Hepatitis B and C Nucleic Acid Test (HBV/HCV NAT), Human Immunodeficiency Virus 1&2 antibodies (HIV 1&2 Ab), HIV Nucleic Acid Test (HIV NAT), Human T-Lymphotropic Virus 1&2 (HTLV 1&2) and Syphilis (RPR/STS).

In June of 2002, the FDA published its draft Guidance for Industry document, Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and variant Creutzfeldt-Jakob Disease (vCJD) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). This document reflects the FDA's current thinking on donor deferral criteria for individuals that may have been exposed to a Bovine Spongiform Encephalopathy (BSE) agent, or Mad Cow disease. The document draft is in the review and comment stage, which precedes the adoption of a final version of the FDA's position on this matter. As a part of this document, the FDA provided a listing of countries applicable to donor deferral. None of the tissue products that Tutogen distributes in the United States or Canada incorporate tissues from countries identified by the FDA.

The Company embarked on a program in 1993 to develop xenografts (tissue derived from animals) as an allograft substitute. As with allografts, xenografts processed using the Company's proprietary *Tutoplast*® process have their biomechanical properties and remodeling capacity preserved with removal of antigenicity and infection risk. Studies have shown that *Tutoplast*® processed xenografts are at least equivalent to allografts as demonstrated by actual clinical use and laboratory studies. To date, the Company has received CE-Marks, the European equivalent to an FDA medical device approval, for bovine pericardium (1998), bovine cancellous bone (1997) and bovine compact (cortical) bone (1999), which permits distribution throughout Europe of products derived from such tissues. Approximately 40% of the total products sold internationally are bovine. Tutogen Germany currently obtains bovine material from a closed herd in an internationally approved source country. In the US, the Company received FDA 510(k) clearance for bovine pericardium in 2000, allowing the Company to market the first xenograft tissues (Tutopatch®) domestically, for indications of general and plastic surgery. Based on such approvals, Tutogen Germany will be able to supply bovine products in the US. The Company is currently evaluating the introduction and timing of bovine products in the US. The unique biomechanical properties of bovine tissue, combined with the absence of the supply constraints associated with allografts, permits the use of xenograft tissues in areas that cannot be optimally addressed with human tissue.

Tutogen allograft tissue recovery providers are FDA registered, state licensed and accredited by the AATB, as appropriate. Tissues are not purchased from these companies, but rather the providers are reimbursed for the costs incurred in the tissue recovery process itself, at the time of delivery. Due to the growing demand for and the limited supply of allograft tissue, the Company is continually seeking to form additional alliances with reputable hospital, tissue bank and organ procurement organization tissue recovery firms and entered into multiple new arrangements during 2006.

In November 2006, the company entered into strategic tissue sourcing agreements with Regeneration Technologies, Inc. (RTI). Under the multi-year agreements, RTI has the first right of refusal to all soft tissue

Table of Contents

used in sports medicine surgeries recovered by Tutogen's tissue recovery providers. The Company, in turn, has the first right of refusal to all dermis, fascia and pericardium recovered by RTI donor services agencies.

Although the Company believes that it has the necessary contractual arrangements in place to ensure that there are sufficient tissues available to meet its needs for the foreseeable future, there can be no assurance that these supplies will continue or materialize as planned. Unavoidable interruptions in tissue supply (such as natural disasters, regulatory changes, financial set-backs) could have a material adverse effect on Tutogen's business operations.

Competition

Tutogen considers itself a leader in safe bioimplants for tissue repair. Tutogen's competitive advantage is based on its *Tutoplast*® process of tissue preservation and viral inactivation. The *Tutoplast*® process consists of multiple steps that assure a safe, viable product and, at the same time, preserves the tissue structure, biomechanics and remodeling characteristics. The *Tutoplast*® process is very robust, and has been proven effective in removing antigenicity and inactivating conventional and unconventional viruses and prions. The implants are terminally sterilized, have a five (5) year shelf life, and can be stored at room temperature. The *Tutoplast*® process has an outstanding safety record. Since its introduction over thirty (30) years ago, more than 1,500,000 procedures have been successfully performed using *Tutoplast*® processed tissues, with no known complications from disease transmission or tissue rejection attributable to the implants. *Tutoplast*® processed implants have been described in more than 400 published scientific papers and peer-reviewed articles.

The majority of the medical procedures suitable for allografts are currently being performed with autografts (tissues derived from the patient), requiring a second surgical procedure. The advantages of autografts include the decreased incident of tissue rejection and disease transmission. The disadvantages are the dual surgical procedures, increased pain and recovery time and the limitation on the amount and quality of tissue. Allograft advantages include the elimination of a second surgical site, resulting in lower infection rates, the possible reduction in surgical procedure time, faster recovery times and lower costs, while disadvantages include availability and possible rejection. Availability and safety are the primary factors in the ability of *Tutoplast*® processed allografts to compete with autografts for use by the surgical community.

The industry in which the Company operates is highly competitive. Processors of allograft tissue for transplantation in the U.S. include commercial manufacturers such as Osteotech, Inc., RTI and LifeCell, Inc., companies well established in the fields of processing and distribution of bone and soft tissue implants, which have substantially greater financial resources than the Company. Not-for-profit tissue banks that procure and process tissue for distribution are considered competitors for certain applications in certain markets. Management believes that the *Tutoplast*® process, with its impressive record for safety in the surgical community, gives the Company a marked advantage over its competitors. However, due to government regulation, disrupted sources of tissue supply and increasing competition, there can be no assurance that the Company will be able to continue to compete successfully. In addition, there can be no assurance that in the future the Company's allografts will be able to compete successfully with new tissue substitutes being developed by other companies.

Growth Strategy

The Company estimates the worldwide market for its present products to be over \$1.25 billion including all procedures in the various fields of use. The Company's existing tissue supply network, established processing facilities and proven *Tutoplast*® technology provides the foundation for continued growth into the foreseeable future. Future growth will be aided by new sources of tissue, new procedures and products, and expansion into new markets. The Company will focus on applications for both human allograft and xenograft tissue implants.

Table of Contents

Besides the Company's internally developed new products and technology, a major component of the Company's growth strategy will be expanding its collaborations with each global distributor. Tutogen will continue to work with each organization to evaluate opportunities for new products and applications, and to determine the potential for international expansion. The ultimate goal is to provide each distributor with a full line of procedure specific implants, for their respective fields of use, and to leverage their sales strength in select international markets.

Currently, the Company's focus is on the introduction of new products and applications for *Tutoplast*® processed tissues. In January 2005, the Company developed, in association with Zimmer Dental, a new bone block to augment ridge restoration. In the U.S. the Puros block graft has been well accepted and is highlighted in various Zimmer Dental training courses. Globally, similar products processed from xenograft tissue, has helped generate growth as the Company focuses on expanding the international market for dental products. Additionally, the Company has developed membranes from *Tutoplast*® processed dermis and pericardium for use as a barrier in dental applications. These products have been used in Europe, and the U.S. launch for pericardium was in February 2006 and for dermis in September 2006. The addition of these new products in the U.S. will provide Zimmer Dental with a full line of products for the dental surgeons.

The spine market for biologic materials was estimated at approximately \$656 million in 2005. This allograft market is split between traditional allograft bone (19%), machined specialty grafts (49%), and demineralized bone matrix (DBM) (32%). Tutogen continues its U.S. collaboration with Zimmer Spine in developing new, highly precise machined specialty grafts. During the fourth quarter of fiscal year 2006, the Company shipped to Zimmer Spine the first two machined specialty grafts (PurosC® cervical graft and PurosA® anterior lumbar interbody fusion graft) for spinal surgery. Zimmer Spine will release these products to the market during 2007. The Company will explore expanding its spinal products internationally during 2007.

During October 2002, the Company entered the European market with Tutomesh(R), a *Tutoplast*® processed xenograft for hernia and abdominal wall repair. It has been well received in Europe, and has already been successfully used in abdominal wall surgery of neonates and children with hernia defects. The Company is evaluating this opportunity globally for both the Tutomesh, as well as for *Tutoplast*® processed dermis. In December 2004, Tutogen received FDA 510(k) marketing clearance for a xenograft product and is currently investigating various options for its distribution in the U.S.

Internationally, the Company has internally developed a line of *Tutoplast*® machined bone implants for the repair of orthopaedic fractures and soft tissue ruptures. The Tutofix® line of implants was released in Europe in 2004. The current strategy is to broaden its release internationally.

In January 2006, Tutogen entered into a four-year exclusive worldwide distribution agreement with Davol, a subsidiary of C. R. Bard, Inc., to promote, market and distribute Tutogen's line of allograft biologic tissues for hernia repair and the reconstruction of the chest and abdominal walls. Under the agreement, Davol paid Tutogen \$3.3 million in fees for the exclusive distribution rights. Davol is a stocking distributor, and entered the hernia market during the fourth quarter of 2006. The US market for biologic grafts used for hernia repair is estimated at \$150 million annually. The Company will work with Davol to grow its new hernia business during 2007 and beyond.

In June 2006, the Company signed a new exclusive distribution agreement with Mentor for the exclusive North American rights for the use of *Tutoplast*® dermis in the dermatology and plastic surgery markets for breast reconstruction. Under the agreement, Mentor will pay the Company an upfront payment of \$.5 million in consideration for these distribution rights. The initial estimated potential market in the U.S. is \$25-50 million. Shipments to Mentor and market release will occur during fiscal year 2007.

Table of Contents**International Operations**

The Company currently has sales in more than 20 countries located primarily in Europe. Approximately 33%, 32% and 42% of the Company's consolidated sales, respectively for fiscal years 2006, 2005, and 2004 were derived from outside the United States, as follows:

	United States	International	Consolidated
	(Revenues in thousands)		
Year ended September 30, 2006	\$ 25,430	\$ 12,517	\$ 37,947
2005	\$ 21,752	\$ 10,108	\$ 31,860
2004	\$ 17,126	\$ 12,204	\$ 29,330

Approximately 40% of total international sales are bovine products and 60% are allograft products. Products are manufactured and supplied out of the Company's manufacturing facilities in Neunkirchen, Germany.

Research and Development

The Company continues to engage in research and development (R&D) activities. The Company follows an internal product development plan and coordinates all R&D activities, including the Zimmer Dental and Zimmer Spine collaborations. R&D expenditures remain at 5% of total sales.

In allograft-related areas, R&D activities focus primarily on the development of surgical solutions and applications, standardized and tailor-made products instead of offering grafting material to the surgeon. Also, continuing progress on the application of the Company's proprietary *Tutoplast*® process to various other tissues has met with success. The Company continues to independently review its processing technology to enhance tissue safety and efficacy. Non-allograft activities relate to explorations into the use of xenografts (specifically bovine), tissue-engineered grafts and improved healing. Clinical studies, evaluation and follow-up are conducted on these activities. The Company is referred to in more than 400 publications. The Company's research efforts are subsidized by its collaboration with non-profit research institutions and its distributors. These activities will be expanded pending the availability of the necessary financial resources.

Customers

The Company has exclusive distribution agreements with Zimmer Dental, Zimmer Spine, Davol, Mentor, Coloplast and IOP. Zimmer Dental and Zimmer Spine accounted for approximately 46% and 8% respectively, of the Company's revenue for the year ended September 30, 2006. No end user customer accounted for more than 10% of the Company's consolidated sales for the fiscal year 2006.

Patents, Licenses and Trademarks

Wherever possible, the Company seeks to protect its proprietary information, products, methods and technology by obtaining patent and trademark protection. The Company has certain patents pending and has multiple registered trademarks covering several countries worldwide. In the United States, the Company is aggressively pursuing 510(k) submissions for its various products or processes and subsequent FDA clearances. The Company believes that it has established itself through the *Tutoplast*® trademark identity and a record of safety and quality assurance that will survive beyond the life of the patents.

Table of Contents**Government Regulation**

The Company procures, processes and markets its tissue products worldwide. Although some standards of harmonization exist, each country in which the Company does business has its own specific regulatory requirements. These requirements are dynamic in nature and, as such, are continually changing. New regulations may be promulgated at any time and with limited notice. While the Company believes that it is in compliance with all existing pertinent international and domestic laws and regulations, there can be no assurance that changes in governmental administrations and regulations will not negatively impact the Company's operations.

In the United States, the Company's allograft products are regulated by the FDA under Title 21 of the Code of Federal Regulations, Parts 1270 and 1271, Current Good Tissue Practice for Human Cell, Tissue, and Cellular and Tissue-Based Products. Xenograft tissues are regulated as medical devices and subject to 21 CFR, Part 820 (Current Good Manufacturing Practices for Medical Devices) and related statutes. The Company has obtained a 510(k) marketing clearance from the FDA for bovine pericardium, for use in general and plastic surgery applications and will be seeking further approvals for other xenograft tissues and indications. In addition, the U.S. operation is subject to certain state and local regulations, as well as compliance to the standards of the tissue bank industry's accrediting organization, the AATB.

In Germany, allografts are classified as drugs and the German government regulates such products in accordance with German drug Law. On April 7, 2004, the European Commission issued a human tissue directive to regulate allografts within the European Union (EU). Tutogen's Neunkirchen facility is presently licensed by the German Health Authorities and in compliance with applicable international laws and regulations, allowing the Company to market its human and animal implant products globally. In June of 2006, the Company received approval to sell its first allograft product into Germany.

The FDA and international regulatory bodies conduct periodic compliance inspections of both the Company's U.S. and German processing facilities. Both operations are registered with the U.S. FDA Center for Biologics Evaluation and Research (CBER) and are certified to ISO 9001:2000 and ISO 13485:2003. The Alachua facility is also accredited by the AATB and is licensed in the states of Florida, New York, California, Maryland, Delaware and Illinois. The Neunkirchen facility is registered with the German Health Authority (BfArM) as a pharmaceutical and medical device manufacturer and is subject to German drug law. The Company believes that worldwide regulation of allografts and xenografts is likely to intensify as the international regulatory community focuses on the growing demand for these implant products and the attendant safety and efficacy issues of citizen recipients. Changes in governing laws and regulations could have a material adverse effect on the Company's financial condition and results of operations. Company management further believes that it can mitigate this exposure by continuing to work closely with government and industry regulators in understanding the basic tenets of the business and participating in the drafting of reasonable and appropriate legislation.

Environmental Regulations

The Company's allografts and xenografts, as well as the chemicals used in processing, are handled and disposed of in accordance with country-specific, federal, state and local regulations. Since 1995, the Company has used outside third parties to perform all biohazard waste disposal.

The Company contracts with independent, third parties to perform all gamma-terminal sterilization of its allografts. In view of the engagement of a third party to perform irradiation services, the requirements for compliance with radiation hazardous waste does not apply, and therefore the Company does not anticipate that having any material adverse effect upon its capital expenditures, results of operations or financial condition. However, the Company is responsible for assuring that the service is being performed in accordance with applicable regulations. Although the Company believes it is in compliance with all applicable environmental

Table of Contents

regulations, the failure to fully comply with any such regulations could result in the imposition of penalties, fines and/or sanctions which could have a material adverse effect on the Company's business.

Employees

As of September 30, 2006, the Company employed a total of 222 full-time employees, of whom 80 full-time employees were employed in the United States and the remainder in Germany. Management believes its relations with its employees are good.

Properties

United States

The Company's domestic facilities are located in Alachua, Florida. The Company previously announced the relocation of the administrative offices to its facility in Alachua which occurred on December 31, 2005. In April 2005, the Company's offices and manufacturing facility in Alachua, Florida expanded from approximately 20,205 square feet to 26,000 square feet of leased space. The Florida lease expires January 31, 2009 with a renewal option through January 31, 2011, at a base rent of approximately \$34,000 per month. There are various options for additional expansion space in the immediate area and the Company believes that it will have sufficient space to meet its current and future needs.

Germany

The Company's facility in Neunkirchen consists of six buildings totaling approximately 33,000 square feet on approximately two acres of land. This property is owned by the Company and should be sufficient in size and condition to handle anticipated production levels for international markets into the foreseeable future. In addition, the Company is renting office space of approximately 23,000 square feet at \$12,500 per month, expiring at various periods in the later part of 2006. The intent is to eliminate and consolidate the current rental offices as part of the facilities expansion project that is currently underway. The expansion project is expected to be completed by the first calendar quarter of 2007.

Legal Proceedings

In 2003, the Company received a proposed judgment in Germany as the result of a dispute between the Company and a former international distributor. The estimated settlement, including legal costs was accrued as a litigation contingency. In 2004, a decision by the court of appeal in Germany resulted in a reduction of the original proposed judgment received against the Company by \$406,000. At September 30, 2006 and September 30, 2005, the Company maintained an accrual of \$385,000 and \$476,000, respectively (approximately 380,000 euros) with respect to the remaining appeal and legal costs. During October 2006, the Company completed a settlement of \$360,000 (or approximately 280,000 euros) with the former international distributor.

On October 12, 2005, the Company issued a voluntary recall of all product units, which utilized donor tissue received from BioMedical Tissue Services/BioTissue Recovery Services (BioMedical). This action was taken because the Company was unable to satisfactorily confirm that BioMedical had properly obtained donor consent. The Company quarantined all BioMedical products in its inventory, having a value of \$1,035,000 and notified all customers and distributors of record regarding this action. In connection with the recall, the Company wrote off \$1,035,000 of inventory during 2005. Additionally, as of September 30, 2005, the Company had accrued \$250,000 of related costs in connection with the recall. As of September 30, 2006, the accrual for these costs was \$0, due in part to actual payments made for such costs and in part to an adjustment made by management during the three months ended March 31, 2006 to reduce the accrual by approximately

Table of Contents

\$150,000 as a result of a change in management's estimate of the total recall related costs. The effect of this adjustment was to reduce cost of revenue by approximately \$150,000.

In January 2006, the Company was named as one of several defendants in a class action suit related to the BioMedical recall. It is management's opinion that it is too early in the process to determine the effect of this class action on the financial condition of the Company.

The Company is party to various claims, legal actions, complaints and administrative proceedings arising in the ordinary course of business. In management's opinion, the ultimate disposition of these matters will not have a material adverse effect on its financial condition, cash flow or results of operations.

MANAGEMENT

The following table sets forth the names and ages of the directors and executive officers of the Company and the Managing Director of our German subsidiary, the positions and offices held by each of them with the Company and the period during which each served in such position. Each Director serves for a term of one (1) year, until his successor is duly elected and qualified.

Name	Age	Positions/Offices	Period Served in Office/Position
G. Russell Cleveland	68	Director	1997 present
Roy D. Crowninshield, Ph.D.	58	Chairman of the Board Chief Executive Officer Director	July 2004 present July 2004 December 2004 2003 present
Neal B. Freeman	66	Director	2005 present
J. Harold Helderman, MD	61	Director	1997 present
Udo Henseler, Ph.D.	67	Director	2005 present
L. Robert Johnston, Jr.	46	Chief Financial Officer	2005 present
Guy L Mayer	55	Chief Executive Officer Director	2005 present
Claude Pering	60	Vice President U.S. Operations	2005 present
Clifton Seliga	54	Vice President Sales and Marketing	2005 present
Adrian J. R. Smith	62	Director	2005 present
Carlton E. Turner, Ph.D.	66	Director	2000 present
Karl H. Koschatzky	59	Managing Director German Subsidiary	2006 present

Table of Contents

G. Russell Cleveland is the President, Chief Executive Officer, sole Director, and majority shareholder of Renaissance Capital Group, Inc. (Renaissance). He is also President, Chief Executive Officer, and a director of Renaissance Capital Growth & Income Fund III, Inc. Mr. Cleveland is a Chartered Financial Analyst with more than thirty-five (35) years experience as a specialist in investments for smaller capitalization companies. A graduate of the Wharton School of Business, Mr. Cleveland has served as President of the Dallas Association of Investment Analysts. Mr. Cleveland currently serves on the Boards of Directors of Renaissance U.S. Growth & Income Trust PLC, Cover-All Technologies, Inc., Digital Recorders, Inc., Integrated Security Systems, Inc., and Camino-Soft, Inc. and Precis, Inc.

Roy D. Crowninshield, Ph.D. is the current Chairman of the Board. From July 2004 to December 2004, Dr. Crowninshield was the Interim Chief Executive Officer of the Company. Prior to joining Tutogen, Dr. Crowninshield served 21 years in various capacities at Zimmer Holdings, including President of Zimmer's U.S. operations and most recently as Zimmer's Chief Scientific Officer. Prior to joining Zimmer, Inc. in 1983, he was a faculty member at the University of Iowa where he led many research projects evaluating the function of total joint implants. He currently holds academic appointments as a professor in the Orthopedic Surgery Department at Rush Medical College in Chicago, Illinois and as an adjunct professor in the College of Engineering of the University of Notre Dame. He holds undergraduate and doctorate degrees from the University of Vermont. He has worked in the orthopedic industry for over 20 years and has extensive experience in the research and development, manufacture, and clinical investigation of orthopedic implants. He has authored more than 100 journal articles, book chapters, and published abstracts in orthopedics and engineering.

Neal B. Freeman is the Chairman and Chief Executive Officer of The Blackwell Corporation (since 1981), an advisory firm, with clients in the communications, defense and wealth management industries. He is also Chairman of the Foundation Management Institute; Chairman of the Board of Advisors of the investment advisory firm, Train Babcock Advisors and Director of North American Management Corp.

J. Harold Helderman, MD has been Dean of Admissions and Professor of Medicine, Microbiology and Immunology at Vanderbilt University, Nashville, Tennessee, since 1999 and has been the Medical Director of the Vanderbilt Transplant Center since 1989. Dr. Helderman received his MD from the State University of New York, Downstate Medical Center in 1971, Summa Cum Laude. In addition to book and monograph writings, he has authored more than 125 publications in his field of transplant medicine. Dr. Helderman is past President of the American Society of Transplantation.

Udo Henseler, Ph.D., Udo Henseler, Ph.D., is currently President and principal/owner of MSI Management-Services-International (a private business since 1994). MSI provides services related to business development for companies at their various stages of their corporate evolution and contract engagements for chief executive officers, for biotechnology and life sciences firms, in domestic and international settings. From 2002 to 2005 Dr. Henseler was the Chief Executive Officer and Chairman and continued until February 2006 as a Director of eGene, Inc., a public biotechnology company. Dr. Henseler has extensive global public and private company leadership experience with over 40 years of combined service, in addition to the foregoing, as: Director and Executive Vice President of ChemoKine Therapeutics Corporation, a biopharmaceutical company; Vice President and Chief Financial Officer of Qualicon Inc., a DuPont subsidiary; Director, Senior Vice President and Chief Financial Officer of the Pharmaceutical Andrx Inc.; Vice President and Chief Financial Officer of Genetic Systems Corp. biopharmaceuticals; Chair Executive Committee, Vice President and Chief Financial Officer of Coulter Corporation life sciences; Group Finance Chief at Beckman, Inc. life-sciences. Dr. Henseler earned his B.A. in Germany, and Master's and Ph.D. degrees from the Claremont Graduate University in Claremont, California. Dr. Henseler is also a Certified Public Accountant and currently serves as Director of Spire Corporation, a publicly traded corporation.

Table of Contents

L. Robert Johnston, Jr. is the Company's Chief Financial Officer. Prior to Tutogen, Mr. Johnston served as Chief Financial Officer of Power Medical Interventions (from 2004 to 2005), a privately held medical device company providing surgical stapling products and prior to Power Medical (from 2002 to 2004) as an independent consultant for Pittsburgh Life Sciences Greenhouse Executive Corps Program. For the four years prior to joining Pittsburgh Life Sciences, Mr. Johnston was Executive Vice President and Chief Financial Officer for Cellomics, Inc. a Pittsburgh, Pennsylvania company providing instrumentation, software and assays for automated cellular analysis for drug discovery in pharma, biotech and academia sectors. Prior experience also includes management positions with Oncormed, Inc. as Chief Financial Officer, American Mobile Satellite Corporation (now Motient Corp) as Assistant Treasurer, and Sovran Bank of Maryland as Assistant Vice President. Mr. Johnston is a 1986 MBA Graduate of the Colgate Darden Graduate School of Business Administration, University of Virginia and received his BA in History and Spanish in 1982 from the University of Virginia.

Guy L. Mayer is the Company's Chief Executive Officer. Prior to joining Tutogen, Mr. Mayer served as Chairman and Chief Executive Officer of Visen Medical (from 2003 to 2004), a private biotech company focused on Molecular Imaging technologies and prior to Visen (from 2000 to 2003), as President and Chief Executive Officer of ETEX Corporation, a private biomedical company based in Cambridge, Massachusetts. For 13 years prior to joining ETEX, Mr. Mayer held various senior positions at Zimmer Inc., then a division of Bristol Myers Squibb, with sales in excess of \$1.2 billion. Mr. Mayer's positions at Zimmer included President Global Products Group, President Orthopedics Implant division, President Zimmer Japan and Sr. Vice President Zimmer International. Prior experience includes general management positions with Picker International in diagnostic imaging, and American Hospital Supply Corporation. Mr. Mayer is a 1974 Graduate of the University of Ottawa and currently serves on the Board of Directors of Spire Corporation, a public corporation.

Claude O. Pering is the Company's Vice President of US Operations. Prior to Tutogen, Mr. Pering served as Principal of CoperTech, LLC (from 2002-2005) providing consulting services to client companies in the medical device, biotechnology and pharmaceutical industries. For the three years prior (1999-2002) Mr. Pering was President and Chief Operating Officer for Hayes Medical, Inc., a manufacturer and worldwide marketer of orthopedic total joint implant products. For the three years prior to joining Hayes Medical, Inc., Mr. Pering was Executive Vice President and Chief Operating Officer for Norian Corporation, a developer, manufacturer and global marketer of biotechnology products that was acquired by Synthes, Inc. Prior experience also includes six years as Vice President Operation/Chief Operations Officer for Ace Medical Company (acquired by DePuy, Inc.) and three years as Corporate Director of Quality Assurance/Group Manager of Quality Engineering for Zimmer, Inc. Mr. Pering is an MBA Graduate, Indiana Wesleyan University, Marion, Indiana and received his BA in Chemistry, Microbiology, Psychology from Drury University, Springfield, Missouri.

Clifton J. Seliga is the Company's Vice President of Sales & Marketing. Prior to Tutogen, Mr. Seliga served as Principal of C. J. Seliga, LLC (from 2002-2005), providing consulting services to senior management, in the areas of business planning, strategic development, marketing, new product planning, sales and distribution. For the three years prior (1998-2001) Mr. Seliga was Senior Vice President, General Manager for ETEX Corporation, a private biomedical company based in Cambridge, Massachusetts. For the six years prior to joining ETEX, Mr. Seliga held various senior positions at Zimmer, Inc., Division of Bristol Myers Squibb, including Vice President Global Marketing and Director of Product Management. Prior experience also includes marketing and sales management positions with Richard-Allan Medical Industries and Richard Wolf Medical Instruments Corporation. Mr. Seliga is an MBA Graduate, Marketing and Management, Northwestern University, Kellogg Graduate School of Management, Evanston, Illinois. He has a Master of Science (Research), Anatomy, St. Louis University and a BA in Biological Science, Chemistry (minor) from Southern Illinois University.

Table of Contents

Mr. Adrian J. R. Smith has been Chief Executive Officer of The Woolton Group since 1997, a strategic advisory group. His business career includes 13 years in the professional services industry and 26 years with two Fortune 500 companies. He has been a Global Managing Partner, Marketing & Communication at Deloitte & Touche, the Chief Executive Officer of Grant Thornton LLP, and a Managing Partner at Arthur Andersen in the early to mid-1990 s. He held senior international management roles with Ecolab Inc. and also with Procter & Gamble. Mr. Smith serves on the board of the Education Foundation of Indian River County in Florida.

Carlton E. Turner, Ph.D., D.Sc. has been the President and Chief Executive Officer of Carrington Laboratories, Inc. (Carrington) (NASDAQ: CARN) since April 1995. Carrington is a research-based pharmaceutical and medical device company in the field of wound care products. Dr. Turner has also served as the Chief Operating Officer from November 1994 to April 1995 and as the Executive Vice President of Scientific Affairs from January 1994 to November 1994 at Carrington. Before that, he was the President, Chief Operating Officer and Founder of Princeton Diagnostic Laboratories of America from 1987 to 1993. From 1981 to 1987 he was an Assistant to President Ronald Reagan with Cabinet Rank and Director of the White House Drug Policy Office. Previously, he was a Research Professor and Director of the Research Institute of Pharmacological Science, University of Mississippi.

Karl H. Koschatzky, Ph.D. is the Managing Director of the Company s German subsidiary. Dr. Koschatzky has served in a variety of capacities within the Company, beginning in 1993 as the Technical Director of international operations. In 1994 Dr. Koschatzky s role expanded to include the planning and implementation of US operations. In 1999 he was promoted to Vice President Research and Development. In the third quarter 2006 Dr. Koschatzky was assigned the additional role of Interim General Manager of German Operations. For the 11 years prior to Tutogen, Dr. Koschatzky served as Manager of Operations, Wound Care Unit, Pfrimmer-Viggo GmbH (1984-1993) and Scientific Manager, Wound Care Business, Lyofil Pfrimmer GmbH (1982-1984). Dr. Koschatzky received his Ph.D. from the University of Erlangen-Nurnberg in 1979 and Diplom-Chemist 1969-1976.

Board Committees

The Board of Directors has an Audit Committee, a Compensation Committee and a Nominating Committee, each consisting entirely of independent directors. The Board of Directors has determined, after considering all the relevant facts and circumstances, that Messrs. Cleveland, Freeman and Smith and Drs. Crowninshield, Helderman, Henseler and Turner are independent directors, as independence is defined by the listing standards of the American Stock Exchange (the Exchange), because they have no material relationship with us.

The Board of Directors has adopted charters for the Audit, Compensation and Nominating Committees describing the authority and responsibilities delegated to each committee by the board. The Board of Directors has also adopted Corporate Governance Guidelines and a Code of Ethics. The charters of the Audit, Compensation and Nominating Committees and the Corporate Governance Guidelines and Code of Ethics have been posted on the Company s website at www.tutogen.com. These documents are also available in print to any stockholder requesting a copy in writing from the corporate secretary at the executive offices set forth in this prospectus.

Table of Contents**Audit Committee**

The Audit Committee of our board of directors consists of Messrs. Cleveland, Smith and Dr. Henseler. Each member of the Audit Committee is independent, as such term is defined in the AMEX listing standards currently in effect and applicable to the Company. Each of the members of the Audit Committee, by virtue of his past employment experience, has considerable knowledge of financial statements, finance, and accounting. Although one member of the Committee has a professional certification in accounting, Mr. Cleveland and Mr. Smith each has significant employment experience as a Chief Executive Officer with financial oversight responsibilities. Mr. Smith has also served as the Chief Operating Officer of various companies. In addition, Mr. Cleveland is a graduate of the Wharton School of Business and has more than thirty-five (35) years of experience as a financial analyst. The Company believes both Mr. Cleveland and Mr. Smith qualify as financial experts under the Securities and Exchange Commission regulations. The background and experience of each of the Audit Committee members is more fully disclosed in their biographies under Nominees for Director.

The mission of the Company's Audit Committee is to ensure accurate and reliable financial reporting by the Company, and to promote shareholder confidence in the reliability of the Company's financial information. To this end, the Audit Committee independently reviews and oversees the Company's internal reporting process, and helps ensure that management develops and adheres to a sound system of internal controls. The Audit Committee also is responsible for retaining and overseeing the Company's independent auditors, and facilitates the auditors' objective review and assessment of the Company's financial statements and its internal reporting practices. The Audit Committee serves as a forum, separate from management, within which the independent auditors, among others, can candidly address issues of concern. To specify and clarify the duties of the Audit Committee, the Company has adopted a formal written charter. The Audit Committee reviews and reassesses the adequacy of its charter on an annual basis.

Nominating Committee

The Nominating Committee of our board of directors consists of Messrs. Smith and Freeman and Drs. Helderman and Henseler. The purpose and responsibilities of the Nominating Committee include the identification of individuals qualified to become board members, the recommendation to the Board of Directors of nominees to stand for election as directors at each election of directors, the development and recommendation to the Board of Directors of a set of corporate governance principles applicable to the Company, the oversight of the selection and composition of Committees of the Board of Directors, and the oversight of the evaluations of the Board of Directors and management. As discussed above, the members of the Nominating Committee are independent, as that term is defined by the listing standards of the Exchange.

Compensation Committee

The Compensation Committee of our board of directors consists of Drs. Helderman and Turner and Mr. Freeman. The mission of the Compensation Committee is to review and approve corporate goals and objectives relevant to the compensation of the Chief Executive Officer, evaluate the performance of the Chief Executive Officer in light of those goals and objectives, and determine and approve the compensation level of the Chief Executive Officer based on this evaluation. The Compensation Committee also recommends to the Board of Directors with respect to, or, as directed by the Board of Directors, determines and approves, compensation of the other executive officers, and considers the grant of stock options to the executive officers under the 1996 and 2006 Stock Option Plan. The Compensation Committee makes every effort to ensure that the compensation plan is consistent with the Company's values and is aligned with the Company's business strategy and goals.

Table of Contents

The compensation program for executive officers consists primarily of base salary, incentive bonuses, discretionary bonuses, and long-term incentives in the form of stock options. Executives also participate in various other benefit plans, including medical and retirement plans that generally are available to all employees.

The Company's philosophy is to pay base salaries to executives at levels that enable the Company to attract, motivate, and retain highly qualified executives, taking into account the possibility of performance-based bonuses. The bonus program is designed to reward individuals for performance based on the Company's financial results as well as the achievement of personal and corporate objectives that contribute to the long-term success in building stockholder value. Stock option grants are intended to result in minimal or no rewards if the price of the Company's common stock does not appreciate, but may provide substantial rewards to executives as stockholders in general benefit from stock price appreciation.

Compensation of Directors

The Company's outside Directors receive a \$6,000 annual retainer, \$1,500 per meeting for attendance at Board meetings, and \$500 per telephonic meeting, plus reimbursement of out-of-pocket expenses. The Chairman of the Board receives \$1,000 per month for his services as Chairman. Additionally, the Company's outside Directors each receive annually options to purchase 12,000 shares of the Company's common stock.

Summary Compensation Table

The following table sets forth the cash and non-cash compensation paid to or accrued to our Chief Executive Officer, other executive officers and Dr. Karl Koschatzky, Managing Director of the Company's German subsidiary, whose compensation exceeded \$100,000 for the fiscal year 2006.

Summary Compensation Table

Name And Principal Position	Fiscal Year	Annual Compensation			Long Term Compensation			
		Salary (\$)	Bonus (\$)	Other Compensation (\$)	Awards	Payouts	All Other Compensation (\$)	
				Annual Compensation (\$)	Restricted Stock Award(s) (\$)	Securities Underlying Options (#)	LTP Payouts (\$)	
Guy L. Mayer (2) Chief Executive Officer	2006	315,000	96,390	0	0	0	0	37,900
	2005	225,000	24,300	0	0	300,000	0	0
L. Robert Johnston, Jr. Chief Financial Officer (3)	2006	149,000	21,803	0	0	60,000	0	26,300
Dr. Karl Koschatzky Managing Director Tutogen Medical GmbH	2006	157,200	9,200	0	0	0	0	47,600
	2005	48,700	13,100	0	0	0	0	51,100
	2004	40,000	0	0	0	0	0	39,100
Claude Pering Vice President US Operations	2006	141,900	24,131	0	0	10,000	0	7,300
	2005	83,100	20,925	0	0	50,000	0	0
Clifton Seliga Vice President US Sales and Marketing	2006	141,900	24,131	0	0	0	0	16,300
	2005	83,100	20,925	0	0	50,000	0	0

- (1) Includes 401(k) contributions, relocation, car allowances and expenses, and pension costs.
- (2) Mr. Mayer was appointed Chief Executive Officer on January 1, 2005.
- (3) Mr. L. Robert Johnston was appointed Chief Financial Officer of the Company in February 2006.

Table of Contents**Employment Agreements**

On December 6, 2004, the Company entered into an employment agreement with Mr. Guy L. Mayer to serve as Chief Executive Officer (CEO) of the Company, commencing January 1, 2005. The term of employment is indefinite and terminates upon written notice by the Company, notice of termination by Mr. Mayer or termination of employment for cause. Minimum notice of termination by the Company, except for cause, is one (1) year from the end of any calendar quarter. Mr. Mayer's current annual base salary is \$347,000. In addition, the employment agreement provides for a bonus for the balance of the Company's fiscal year 2006 in an amount up to sixty percent (60%) of his earned salary for fiscal 2006, subject to the Company realizing certain performance goals based on revenue and operating income. In addition, Mr. Mayer was granted a ten (10) year option, upon commencement of employment, to purchase 250,000 shares of the Company's common stock, exercisable at the market price on the date of grant, twenty-five percent (25%) on the date of grant and twenty-five percent (25%) on each of the first three (3) anniversaries. For his performance, Mr. Mayer was granted a ten (10) year option to purchase 50,000 shares of the Company's common stock, exercisable at the market price on the date of grant, twenty-five percent (25%) on the date of the grant and twenty-five percent (25%) of the first three (3) anniversaries. Mr. Mayer has a change of control Agreement whereby he is entitled to twenty-four (24) months salary including medical benefits, in the event he is terminated as a result of change of control.

The Company has a severance agreement with L. Robert Johnston, Jr., Chief Financial Officer. Pursuant to that agreement, upon written notice of his termination, the Company will provide him with six (6) months salary including medical benefits. Mr. Johnston's annual base salary is currently \$200,000. The Company also provides an annual bonus in an amount up to thirty percent (30%) of his annual base salary, subject to the satisfaction of reasonable performance goals established by the board. In addition, Mr. Johnston has a change of control agreement whereby he is entitled to six (6) months salary including medical benefits in the event he is terminated as the result of a change of control of the Company.

In connection with their employment, the Company has agreed to a six (6) month severance package for Messrs. Pering and Seliga in the event of termination of employment due to a change of control of the Company.

Management Bonus Incentive Plan

The Company provides a management bonus incentive plan based on operating goals agreed upon by the Board of Directors and individual MBO's (Management by Objectives), both established on or about the beginning of each fiscal year. The incentive bonus can range up to thirty percent (30%) of salary for key managers to sixty percent (60%) for the Chief Executive Officer.

Stock Option Plans

The Company has a 1996 and 2006 Incentive and Non-Statutory Stock Option Plan (the "Option Plans") to attract, maintain and develop management by encouraging ownership of the Company's Common Stock by Directors, Officers and other key employees. The following is a summary of the provisions of the 1996 Plan. This summary is qualified in its entirety by reference to the 1996 and 2006 Plan, a copy of which may be obtained from the Company.

Table of Contents

The Option Plans authorizes the granting of both incentive stock options, as defined under Section 422 of the Internal Revenue Code of 1986 (ISO), and non-statutory stock options (NSO) to purchase Common Stock. All employees of the Company and its affiliates are eligible to participate in the 1996 Plan. The Option Plans also authorize the granting of NSOs to non-employee Directors and consultants of the Company.

The 1996 Plan expired in February 2006 and no further options can be granted under the Plan. The 1996 Plan was superseded by the 2006 Plan (1,000,000 shares authorized), adopted by the Board of Directors on December 5, 2005 and ratified by the shareholders on March 13, 2006. Under the 2006 Plan, options may be granted at not less than the fair market value on the date of grant. Options may be subject to a vesting schedule and expire four, five or 10 years from grant.

Pursuant to the 2006 Plan, an option to purchase 12,000 shares of Common Stock are granted automatically to each outside Director who is newly elected to the Board. In addition, an option to purchase 12,000 shares of Common Stock are granted automatically, on the date of each annual meeting of shareholders of the Company, to each outside Director who has served in that capacity for the past six (6) months and continues to serve following such meeting.

The Board of Directors or the Compensation Committee is responsible for the administration of the Plans and determines the employees to which options will be granted, the period during which each option will be exercisable, the exercise price, the number of shares of the Common Stock covered by each option, and whether an option will be a non-qualified or an incentive stock option. The exercise price, however, for the purchase of shares subject to such an option, cannot be less than one hundred percent (100%) of the fair market value of the Common Stock on the date the option is granted. The Compensation Committee has no authority to administer or interpret the provisions of the 2006 Plan relating to the grant of options to outside Directors. The current members of the Compensation Committee are Dr. Turner, Dr. Helderman and Mr. Freeman.

No option granted pursuant to either Option Plan is transferable otherwise than by will or the laws of descent and distribution. The term of each option granted to an employee under the 2006 Plan is determined by the Board of Directors or the Compensation and Stock Option Committee, but in no event may such term exceed ten (10) years from the date of grant. Each option granted to an outside Director under the 2006 Plan shall be exercisable in whole or in part during the four (4) year period commencing on the date of the grant of such option. Any option granted to an outside Director should remain effective during the entire term, regardless of whether such Director continues to serve as a Director. The purchase price per share of Common Stock under each option granted to a Director will be the fair market value of such share on the date of grant.

The vesting period for options granted under the 2006 Plan are set forth in an option agreement entered into with the optionee. Options granted to an optionee terminate three (3) months after termination of employment except for death and disability. In the event of death or disability, all vested options expire one hundred eighty (180) days from the date of death or termination of employment due to disability. Upon the occurrence of a change in control of the Company, the maturity of all options then outstanding under the 2006 Plan will be accelerated automatically, so that all such options will become exercisable in full with respect to all shares that have not been previously exercised or become exercisable. A change in control includes certain mergers, consolidation, and reorganization, sales of assets, or dissolution of the Company.

As of September 30, 2006, there were outstanding options to purchase 2,221,368 shares of common stock under the 1996 Plan. The 2006 Plan presently reserves 1,000,000 shares of the Company's Common Stock for issuance thereunder. As of September 30, 2006, options have been granted to purchase 17,500 shares and 982,500 shares remain available under the 2006 Plan. Unless sooner terminated, the 2006 Plan will expire on December 5, 2015.

Table of Contents

The following table provides information as to options granted to the persons named in the Summary Compensation Table. All such options were granted under the Company's 1996 Stock Option Plan.

Options Granted in Fiscal Year 2006

	Number of Securities Underlying Options Granted (#)	Percent of Total Options Granted to Employees	Exercise or Base Price (\$/Sh)	Expiration Date	Potential Realizable Value at Assumed Annualized Rates of Stock Price Appreciation for Option Term ⁽²⁾	
					5%	10%
L. Robert Johnston, Jr. ⁽¹⁾	60,000	56%	\$2.95	1/17/2016	\$111,314	\$282,092
Claude Pering	10,000	9%	\$3.12	12/5/2015	\$19,622	\$49,725

(1) Stock options related to Mr. Johnston's appointment as the new Chief Financial Officer of the Company in February 2006.

(2) Potential realizable value is based on the assumption that the common stock appreciates at the annual rate shown (compounded annually) from the due date of grant until the expiration of the option term. These numbers are calculated based on the requirements of the SEC and do

not reflect the
Company's
estimate of
future price
growth.

The following table sets forth information as to the value of unexercised options held by the persons named in the Summary Compensation table at September 30, 2006. The closing price of the Company's common stock at September 30, 2006 was \$4.50.

Name	Fiscal Year-End Option Values		Value of Unexercised in-the-Money Options at	
	Number of Unexercised Options at		September 30, 2006	
	September 30, 2006	September 30, 2006	September 30, 2006	September 30, 2006
	Exercisable	Unexercisable	Exercisable	Unexercisable
Guy L. Mayer	150,000	150,000	\$245,750	\$245,750
L. Robert Johnston, Jr.	15,000	45,000	23,250	69,750
Dr. Karl Koschatzky	115,418	11,250	282,950	18,338
Claude Pering	12,500	47,500	14,750	58,050
Clifton Seliga	12,500	37,500	14,750	44,250

401(k) Plan

The Board of Directors of the Company approved a tax-deferred investment plan (the 401(k) Plan) effective in 1991. All full-time employees of the Company may elect to participate in the 401(k) Plan, once he or she has completed six (6) months of service to the Company. Under the 401(k) Plan, a participating employee is given an opportunity to make an elective contribution under a salary deferral savings arrangement of up to the maximum allowed by law. In addition, the Company makes a separate matching contribution, in an amount equal to fifty percent (50%) of the amount contributed by the employee. An employee of the Company may elect to retire after attaining age 65. At that time, the total amount contributed, plus any accumulated earnings, will be used to provide a lump sum payment to any retiring participant in the 401(k) Plan. Participants terminating employment prior to normal retirement date will be fully vested in their own elective contribution. Funds accumulated from the Company's matching contributions will vest over a four (4) year period.

Table of Contents**Related Party Transactions**

The Company has an exclusive license and distribution agreement with Zimmer Spine, whereby Zimmer Spine has been granted the right to act as the Company's exclusive distributor of bone tissue for spinal applications in the United States. For the years ended September 30, 2006, 2005 and 2004 product sales to Zimmer Spine totaled approximately \$2.9 million, \$3.1 million and \$4.9 million, respectively. Accounts receivable from Zimmer Spine were approximately \$952,000 and \$44,000 at September 30, 2006 and September 30, 2005, respectively.

The Company has also engaged Zimmer Dental to act as an exclusive distributor for the Company's bone tissue for dental applications in the United States and certain international markets. Under this distribution agreement, the Company sells directly to Zimmer Dental's customers. For the years ended September 30, 2006, 2005 and 2004, Zimmer Dental was paid commissions aggregating approximately \$7.2 million, \$6.1 million and \$3.2 million, respectively. Accounts payable to Zimmer Dental total approximately \$1.9 million and \$1.7 million at September 30, 2006 and September 30, 2005, respectively.

As of September 30, 2006, Zimmer CEP (formerly Centerpulse) USA Holding Co., a subsidiary of Zimmer Holdings, is a 32% owner of the Company's outstanding shares of Common Stock.

On March 10, 2006, Zimmer Holdings filed an amended Schedule 13 (d) expressing its intention to initiate discussions with the Company which could possibly include further investment by Zimmer Holdings in securities of the Company or the acquisition by Zimmer Holdings of some or all of the outstanding common stock of the Company.

On August 9, 2006, representatives of Zimmer Holdings contacted the management of the Company telephonically to propose to the Company a non-binding indication of interest (the Indication of Interest) with respect to a proposed acquisition of the Company at an indicative price range of \$5.00 - \$6.00 per share of Common Stock. Later on the same day, the Company contacted Zimmer Holdings and rejected the Indication of Interest. Subsequently, Zimmer Holdings filed an amended 13(d) expressing that they had determined not to pursue an acquisition of the Company at that time, but based on other factors deemed relevant by Zimmer Holdings, including, but not limited to, the price and availability of Common Stock, subsequent developments affecting Zimmer Holdings and the Company, the business prospects of Zimmer Holdings and the Company, general stock market and economic conditions and tax considerations, Zimmer Holdings may formulate other plans and/or make other proposals and take other actions with respect to its investment in the Company that it deems to be appropriate.

Liability and Indemnification

The Company's by-laws provide for the indemnification of any person who is or was a party, or is threatened to be made a party, to any threatened, pending or completed action, suit or other type of proceeding (other than an action by or in the right of the corporation), whether civil, criminal, administrative, investigative or otherwise, and whether formal or informal, by reason of the fact that such person is or was a director or officer of the Company or is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against judgments, amounts paid in settlement, penalties, fines (including an excise tax assessed with respect to any employee benefit plan) and expenses (including attorneys' fees, paralegals' fees and court costs) actually and reasonably incurred in connection with any such action, suit or other proceeding, including any appeal thereof, if such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the best interests of the

Table of Contents

Company and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person's conduct was unlawful. The termination of any such action, suit or other proceeding by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner that such person reasonably believed to be in, or not opposed to, the best interests of the Company or, with respect to any criminal action or proceeding, had reasonable cause to believe that such person's conduct was unlawful.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

The following table sets forth certain information regarding the beneficial ownership of the Company's common stock as of November 30, 2006, by (i) each person known to the Company to own beneficially more than five percent (5%) of its common stock, (ii) each director and executive officer of the Company, and (iii) all directors and executive officers as a group. As of November 30, 2006, there were 16,413,185 shares of common stock issued and outstanding.

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Owner	Percentage of Class
SPV 1996 LP 101 Finsbury Pavement London, England EC2A 1EJ	(1)(2) 1,896,794	(3) 11.56
Zimmer CEP (formerly Centerpulse) USA Holding Co. Subsidiary of Zimmer Holdings, Inc. 345 East Main Street Warsaw, IN 46580	5,297,124	32.27
G. Russell Cleveland (4)	124,300	*
Roy D. Crowninshield, Ph.D. (5)	62,000	*
Neal B. Freeman (6)	44,500	*
Dr. J. Harold Helderman (7)	117,000	*
Udo Henseler, Ph.D. (8)	24,500	*
L. Robert Johnston, Jr.(8)	15,000	*
Guy L. Mayer (8)	150,000	*
Claude Pering (8)	15,000	*
Clifton Seliga (9)	13,500	*
Adrian J. R. Smith (8)	24,500	*
Carlton E. Turner (10)	57,000	*

All directors and officers as a group (11 persons)	41	600,000	3.5
--	----	---------	-----

Table of Contents

- * Less than one percent (1%).

- 1 In accordance with Rule 13d-3 promulgated pursuant to the Exchange Act, a person is deemed to be the beneficial owner of the security for purposes of the rule if he or she has or shares voting power or dispositive power with respect to such security or has the right to acquire such ownership within sixty (60) days. As used herein, voting power is the power to vote or direct the voting of shares and dispositive power is the power to dispose or direct the disposition of shares, irrespective of any economic interest therein.

- 2 Except as otherwise indicated by footnote, the persons named in the table have sole voting and investment power with respect to all of the common

stock beneficially owned by them.

- 3 In calculating the percentage ownership for a given individual or group, the number of shares of common stock outstanding includes unissued shares subject to options exercisable within sixty (60) days after November 30, 2006 held by such individual or group.
- 4 Includes 47,000 shares of common stock issuable upon exercise of options exercisable within sixty (60) days.
- 5 Includes 42,000 shares of common stock issuable upon exercise of options exercisable within sixty (60) days.
- 6 Includes 24,500 shares of common stock issuable upon exercise of options exercisable within sixty (60) days.
- 7 Includes 87,000 shares of common stock issuable upon exercise of options

- exercisable within sixty (60) days.
- 8 All of the shares of common stock beneficially owned by Messrs. Henseler, Johnston, Mayer, Pering, Seliga and Smith are derivative securities issuable upon exercise of options exercisable within sixty (60) days.
- 9 Includes 12,500 shares of common stock issuable upon exercise of options exercisable within sixty (60) days.
- 10 Includes 47,000 shares of common stock issuable upon exercise of options exercisable within sixty (60) days.

SELLING STOCKHOLDER

The table set forth below contains certain information regarding the beneficial ownership of shares of common stock held by the Selling Stockholder as of November 30, 2006 and the number of shares of common stock covered by this prospectus.

Name of Selling Stockholder	Shares Beneficially Owned Prior to Offering		Shares Beneficially Owned After the Offering	
	Number	Percent⁽¹⁾	Number	Percent⁽²⁾
Azimuth	757,524	4.6%		

(1) Applicable percentage ownership is based on 16,413,185

shares of
common stock
outstanding as
of
November 30,
2006.

- (2) Assumes that all
shares of
common stock
covered by this
offering will be
issued and sold.

We may require the Selling Stockholders to suspend the sales of the securities offered by this prospectus upon the occurrence of any event that makes any statement in this prospectus or the related registration statement untrue in any material respect or that requires the changing of statements in these documents in order to make statements in those documents not misleading.

PLAN OF DISTRIBUTION

The Selling Stockholders may, from time to time, sell all or a portion of the shares of common stock on any market upon which the common stock may be quoted (currently AMEX), in privately negotiated transactions or otherwise.

Table of Contents

Any broker-dealer or agent that participates with the Selling Stockholder in the sale of the shares of common stock may be deemed to be underwriters within the meaning of the Securities Act in connection with these sales. In that event, any commissions received by the broker-dealers or agents and any profit on the resale of the shares of common stock purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act.

DESCRIPTION OF CAPITAL STOCK

As of November 30, 2006, our authorized capital stock consists of 30,000,000 shares of common stock, of which 16,413,185 shares are outstanding and 1,000,000 shares of Preferred Stock, none of which are outstanding.

Common Stock

Each shareholder of common stock is entitled to one (1) vote for each share held on all matters submitted to a vote of stockholders, including the election of directors.

Subject to the rights of the holders of any outstanding shares of preferred stock and any restrictions that may be imposed by any lender on the Company, holders of common stock are entitled to receive such dividends, if any, as may be declared by the board of directors out of funds legally available for such purpose. Upon the liquidation,, dissolution or winding-up of the Company, after payment in full of creditors and any liquidation preference payable to the holders of any preferred stock, the remaining assets of the Company will be distributed ratably to the holders of the common stock, in proportion to the number of shares held by them.

Holders of common stock are entitled to one vote per share on all matters submitted a vote of the shareholders. Because holders of common stock do not have cumulative voting rights in the election of directors, the holders of a majority of the shares of common stock represented at a meeting can elect all the directors. Holders of common stock do not have preemptive rights to subscribe for or purchase any additional shares of capital stock issued by the Company. All outstanding shares of common stock are, and the shares of common stock offered hereby will be, when issued, duly authorized, validly issued, fully paid and nonassessable.

Preferred Stock

No shares of preferred stock are outstanding, but the board of directors is empowered by the Company's Certificate of Incorporation to designate and issue from time to time one or more series of preferred stock without shareholder approval. The board of directors has the power to establish the preferences, limitations and optional or other special rights of each series of preferred stock so issued. Because the board of directors has the power to establish the preferences and rights of each series of preferred stock, it may afford the holders of any series of preferred stock preferences and rights, voting otherwise senior to the rights of holders of common stock. The board of directors, without approval of the holders of common stock, could issue preferred stock with voting rights that could adversely affect the voting power of holders of common stock. The issuance of preferred stock could be used to delay or prevent a change in control of the Company opposed by the board of directors. The Company has no present intention to issue any shares of preferred stock.

Under the Company's Certificate of Incorporation, the board of directors is authorized to divide the preferred stock into one or more series with such designations, assigned values, preferences and relative, participating, optional or other rights, qualifications, limitations or restrictions thereof as provided in the adopting resolution or resolutions providing for the issue of such series.

Table of Contents

Shareholders Rights Agreement

The Company has adopted a Shareholders Rights Agreement pursuant to which each share of common stock carries with it a dividend of one (1) preferred share purchase right. The rights protect shareholders from coercive or otherwise unfair takeover tactics. In general, it works by imposing a significant penalty upon any person or group (Acquiring Person), with certain exceptions, that acquires twenty percent (20%) or more of our outstanding common stock without the approval of our directors.

In the case of Zimmer Holdings and its affiliates, since Zimmer, at the time of adoption of the Shareholders Rights Agreement, owned approximately thirty-three percent (33%) of our outstanding shares, an increase in one percent (1%) or more would trigger the rights program.

The rights are exercisable ten (10) days after a public announcement that a person or group has acquired beneficial ownership of more than twenty percent (20%) of our outstanding common stock or commences a tender offer resulting in such beneficial ownership.

Each right allows the holder (other than an Acquiring Person) to purchase from the Company one one-hundredth of a share of preferred stock for \$35.00 once they become exercisable. This then allows a shareholder to purchase for \$35.00 shares of our common stock having a market value of \$70.00.

Transfer Agent

The transfer agent for the common stock is the Computershare Investors Services, 7530 Lucerne Drive, Suite 100, Cleveland, Ohio 44130.

LEGAL MATTERS

The validity of the shares of common stock to be issued in connection with the offering is being passed upon for us by our counsel, Williams Schifino Mangione & Steady, P.A., Tampa, Florida.

EXPERTS

The financial statements as of September 30, 2006 and 2005, and for each of the three years in the period ended September 30, 2006 included in this prospectus and the related financial statement schedule included elsewhere in the registration statement have been audited by Deloitte & Touche LLP, an independent registered public accounting firm, as stated in their reports appearing herein and elsewhere in the registration statement, and have been so included in reliance upon the reports of such firm given upon their authority as experts in accounting and auditing.

AVAILABLE INFORMATION

We are required to file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at <http://www.sec.gov>.

You may also read and copy any materials we file with the Securities and Exchange Commission at the SEC's Public Reference Room at 100 F Street N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms.

We have filed with the SEC a registration statement on Form S-1, under the Securities Act with respect to the securities offered under this prospectus. This prospectus, which forms a part of that registration statement, does not contain all information included in the registration statement. Certain information is

Table of Contents

omitted and you should refer to the registration statement and its exhibits. With respect to references made in this prospectus to any contract or other document of Tutogen, the references are not necessarily complete and you should refer to the exhibits attached to the registration statement for copies of the actual contract or document. You may review a copy of the registration statement at the SEC's public reference room. Please call the SEC at 1-800-SEC-0330 for further information on the operation of the public reference rooms. Our filings and the registration statement can also be reviewed by accessing the SEC's website at <http://www.sec.gov>.

We maintain an internet website www.tutogen.com wherein information about the Company is readily available. In addition, we send to our shareholders annual reports containing audited financial statements with a report thereon by its independent certified public accountants.

No finder, dealer, sales person or other person has been authorized to give any information or to make any representation in connection with this offering other than those contained in this prospectus and, if given or made, such information or representation must not be relied upon as having been authorized by Tutogen. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any of the securities offered hereby by anyone in any jurisdiction in which such offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such offer or solicitation. Neither the delivery of this prospectus nor any sale made hereunder shall, under any circumstances, create any implication that the information contained herein is correct as of any time subsequent to the date of this prospectus.

Table of Contents

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders of Tutogen Medical, Inc.

Alachua, Florida

We have audited the accompanying consolidated balance sheets of Tutogen Medical, Inc. and subsidiaries (the Company) as of September 30, 2006 and 2005, and the related consolidated statements of (loss) income and comprehensive (loss) income, shareholders' equity and cash flows for each of the three years in the period ended September 30, 2006. Our audits also included the financial statement schedule listed in Item 27. These financial statements and financial statement schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on the financial statements and financial statement schedule based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, such consolidated financial statements present fairly, in all material respects, the financial position of Tutogen Medical, Inc. and subsidiaries as of September 30, 2006 and 2005, and the results of their operations and their cash flows for each of the three years in the period ended September 30, 2006, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, such financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, present fairly in all material respects the information set forth therein.

/s/ DELOITTE & TOUCHE LLP

Orlando, Florida

December 27, 2006

F-1

Table of Contents

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
 CONSOLIDATED BALANCE SHEETS
 SEPTEMBER 30, 2006 AND 2005
 (In Thousands, Except for Share Data)

	2006	2005
ASSETS		
Current Assets		
Cash and cash equivalents	\$ 3,463	\$ 3,562
Accounts receivable net of allowance for doubtful accounts of \$483 in 2006 and \$462 in 2005	6,202	3,473
Inventories net	12,678	9,554
Deferred tax asset, net	471	1,149
Other current assets	1,436	623
	24,250	18,361
Property, plant and equipment, net	12,940	6,612
Other assets	424	
Deferred tax asset, net	1,303	1,232
TOTAL ASSETS	\$ 38,917	\$ 26,205
LIABILITIES AND SHAREHOLDERS EQUITY		
Current Liabilities		
Accounts payable	\$ 1,346	\$ 1,365
Accrued expenses and other current liabilities	4,314	4,977
Accrued commissions	1,918	1,765
Short-term borrowings	5,783	1,048
Current portion of deferred distribution fees	1,577	589
Current portion of long-term debt	1,097	184
	16,035	9,928
Noncurrent Liabilities		
Noncurrent deferred distribution fees and other noncurrent liabilities	3,988	1,925
Long-term debt	3,673	630
TOTAL LIABILITIES	23,696	12,483
Shareholders Equity :		
Common stock, \$0.01 par value, 30,000,000 shares authorized; 16,197,235 and 15,932,960 shares issued and outstanding	162	159

Edgar Filing: TUTOGEN MEDICAL INC - Form S-1

Additional paid-in capital	37,751	36,381
Accumulated other comprehensive income	2,393	1,678
Accumulated deficit	(25,085)	(24,496)
Total shareholders' equity	15,221	13,722
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	\$ 38,917	\$ 26,205

See accompanying Notes to Consolidated Financial Statements

F-2

Table of Contents

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
 CONSOLIDATED STATEMENTS OF (LOSS) INCOME AND COMPREHENSIVE (LOSS) INCOME
 YEARS ENDED SEPTEMBER 30, 2006, 2005 AND 2004

(In Thousands, Except for Share and Per Share Data)

	2006	2005	2004
REVENUE	\$ 37,947	\$ 31,860	\$ 29,330
COST OF REVENUE	16,336	20,129	11,852
Gross profit	21,611	11,731	17,478
OPERATING EXPENSES			
General and administrative	7,803	5,790	4,151
Distribution and marketing	12,261	11,509	8,737
Research and development	1,834	1,659	1,432
	21,898	18,958	14,320
OPERATING (LOSS) INCOME	(287)	(7,227)	3,158
FOREIGN EXCHANGE LOSS	(311)	(173)	(700)
OTHER INCOME	108	77	99
INTEREST EXPENSE	(293)	(130)	(118)
	(496)	(226)	(719)
(LOSS) INCOME BEFORE INCOME TAX (BENEFIT)			
EXPENSE	(783)	(7,453)	2,439
Income tax (benefit) expense	(194)	(436)	1,306
NET (LOSS) INCOME	\$ (589)	\$ (7,017)	\$ 1,133
Other Comprehensive Income (Loss):			
Foreign currency translation adjustments	715	(570)	2,167
COMPREHENSIVE INCOME (LOSS)	\$ 126	\$ (7,587)	\$ 3,300
AVERAGE SHARES OUTSTANDING FOR BASIC EARNINGS (LOSS) PER SHARE	16,027,469	15,919,286	15,734,470

Edgar Filing: TUTOGEN MEDICAL INC - Form S-1

BASIC (LOSS) EARNINGS PER SHARE	\$	(0.04)	\$	(0.44)	\$	0.07
AVERAGE SHARES OUTSTANDING FOR DILUTED EARNINGS (LOSS) PER SHARE		16,027,469		15,919,286		16,469,443
DILUTED (LOSS) EARNINGS PER SHARE	\$	(0.04)	\$	(0.44)	\$	0.07

See accompanying Notes to Consolidated Financial Statements
F-3

Table of Contents

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEARS ENDED SEPTEMBER 30, 2006, 2005 AND 2004
(In Thousands)

	2006	2005	2004
Cash flows (used in) provided by operating activities			
Net (loss) income	\$ (589)	\$ (7,017)	\$ 1,133
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:			
Depreciation and amortization	778	984	760
Amortization of deferred distribution fees revenue	(835)	(640)	(640)
Amortization of debt discount	69		
Reserve for bad debt	19	308	(83)
Provision for inventory write-downs	246	889	(597)
Share-based compensation	451		
Deferred income taxes	797	(505)	869
Changes in assets and liabilities:			
Accounts receivable	(2,632)	1,106	807
Inventories	(3,394)	3,771	(1,810)
Other assets	(513)	798	(241)
Accounts payable and other accrued expenses	145	(497)	(894)
Accrued commissions	153	244	1,076
Deferred distribution fees	3,550		
Net cash (used in) provided by operating activities	(1,755)	(559)	380
Cash flows used in investing activities			
Deposits on purchases of property and equipment	(300)		
Purchase of property and equipment	(5,690)	(1,682)	(1,758)
Net cash used in investing activities	(5,990)	(1,682)	(1,758)
Cash flows provided by financing activities			
Issuance of common stock	647	36	366
Proceeds from long-term borrowings and capital lease arrangements	2,365		224
Proceeds from short-term borrowings	2,910	1,508	
Issuance of convertible debt	3,000		
Debt issuance costs	(263)		
Repayment of short-term borrowings	(163)	(400)	
Repayment of long-term debt	(593)	(164)	(95)
Net cash provided by financing activities	7,903	980	495
Effect of exchange rate changes on cash and cash equivalents	(257)	(240)	897

Edgar Filing: TUTOGEN MEDICAL INC - Form S-1

Net (decrease) increase in cash and cash equivalents	(99)	(1,501)	14
Cash and cash equivalents at beginning of period	3,562	5,063	5,049
Cash and equivalents at end of period	\$ 3,463	\$ 3,562	\$ 5,063
Supplemental cash flow disclosures			
Interest paid	\$ 578	\$ 127	\$ 118
Income taxes paid	\$	\$ 149	\$ 251
Non-cash investing and financing activities relating to capital lease arrangement	\$ 987	\$	\$

See accompanying Notes to Consolidated Financial Statements

F-4

Table of Contents

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
 CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
 YEARS ENDED SEPTEMBER 30, 2006, 2005 AND 2004

(In Thousands, Except for Share Data)

	ACCUMULATED					COMMON SHARES ISSUED AND OUTSTANDING
	COMMON STOCK (\$01 PAR)	ADDITIONAL PAID-IN CAPITAL	OTHER COMPREHENSIVE INCOME (1)	ACCUMULATED DEFICIT	TOTAL	
BALANCE, SEPTEMBER 30, 2003	\$ 157	\$ 35,980	\$ 81	\$ (18,612)	\$ 17,606	15,667,110
Stock issued on exercise of options	2	365			367	248,850
Net income				1,133	1,133	
Foreign currency translation adjustment			2,167		2,167	
	-					
BALANCE, SEPTEMBER 30, 2004	159	36,345	2,248	(17,479)	21,273	15,915,960
Stock issued on exercise of options		36			36	17,000
Net loss				(7,017)	(7,017)	
Foreign currency translation adjustment			(570)		(570)	
	-					
BALANCE, SEPTEMBER 30, 2005	159	36,381	1,678	(24,496)	13,722	15,932,960
Stock issued on exercise of options	3	644			647	264,275
Warrants issued		275			275	
Share-based compensation		451			451	
Net loss				(589)	(589)	
Foreign currency translation adjustment			715		715	
	-					
BALANCE, SEPTEMBER 30,	\$ 162	\$ 37,751	\$ 2,393	\$ (25,085)	\$ 15,221	16,197,235

2006

- (1) Represents
foreign currency
translation
adjustments.

See accompanying Notes to Consolidated Financial Statements

F-5

Table of Contents

TUTOGEN MEDICAL, INC. AND SUBSIDIARIES
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 YEARS ENDED SEPTEMBER 30, 2006, 2005 AND 2004

(In Thousands, Except for Share Data)

1. OPERATIONS AND ORGANIZATION

Tutogen Medical, Inc. with its consolidated subsidiaries (the Company) processes, manufactures and distributes worldwide, specialty surgical products and performs tissue processing services for neuro, orthopedic, reconstructive and general surgical applications. The Company's core business is processing human donor tissue, utilizing its patented TUTOPLAST® process, for distribution to hospitals and surgeons. The Company processes at its two manufacturing facilities in Germany and the United States and distributes its products and services to over 20 countries worldwide.

2. SIGNIFICANT ACCOUNTING POLICIES

Significant accounting policies of the Company are presented below.

Principles of Consolidation - The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany transactions and balances are eliminated in consolidation.

Foreign Currency Translation - The functional currency of the Company's German subsidiary is the Euro. Assets and liabilities of foreign subsidiaries are translated at the period end exchange rate while revenues and expenses are translated at the average exchange rate for the period. The resulting translation adjustments, representing unrealized, noncash gains and losses are made directly to comprehensive income. Gains and losses resulting from transactions of the Company and its subsidiaries, which are made in currencies different from their own, are included in income as they occur and are included in Foreign Exchange Loss in the Consolidated Statements of (Loss) Income and Comprehensive (Loss) Income. The Company recognized transaction losses of \$311, \$173, and \$700 in 2006, 2005 and in 2004, respectively.

Fair Value of Financial Instruments - The carrying value of all current assets and current liabilities approximates fair value because of their short-term nature. The estimated fair value of all other amounts has been determined by using available market information and appropriate valuation methodologies. The carrying value of long-term debt approximates fair value.

Cash and Cash Equivalents - The Company considers all highly liquid investments purchased with a remaining maturity of three months or less to be cash equivalents. For cash and cash equivalents, the carrying amount approximates fair value due to the short maturity of those instruments.

Inventories - Inventories are valued at the lower of cost or market. Work in process and finished goods includes costs attributable to direct labor and overhead. Impairment charges for slow moving, excess and obsolete inventories are recorded based on historical experience, current product demand including meeting periodically with distributors, regulatory considerations, industry trends, changes and risks and the remaining shelf life. As a result of this analysis, the Company reduces the carrying value of any impaired inventory to its fair value, which becomes its new cost basis. If the actual product life cycles, demand or general market conditions are less favorable than those projected by management, additional inventory impairment charges may be required which would affect future operating results due to increases costs from the resulting adjustment. The adequacy of these impairment charges is evaluated quarterly.

Debt Issuance Costs - Debt issuance costs include costs incurred to obtain financing. Upon funding of debt offerings, deferred financing costs are capitalized as debt issuance costs and are amortized to interest expense using the straight-line method, which approximates the effective interest method, over the life of the related debt. At September 30, 2006, debt issuance costs were \$154 and are included in other assets in the accompanying balance sheets. The debt issuance costs amortize at \$17 monthly through June 2007.

Table of Contents

Property, Plant and Equipment - Property, plant and equipment are stated at cost. Depreciation is computed by using the straight-line method over the following estimated useful lives of the assets:

	40
Building and improvements	years
	3-10
Machinery, equipment, furniture and fixtures	years

Amortization expense associated with assets financed by capital lease are included in the depreciation and amortization line of the consolidated cash flow statements.

Impairment of Long-Lived Assets Periodically, the Company evaluates the recoverability of the net carrying amount of its property, plant and equipment by comparing the carrying amounts to the estimated future undiscounted cash flows generated by those assets. If the sum of the estimated future undiscounted cash flows were less than the carrying amount of the asset, a loss would be recognized for the difference between the fair value and the carrying amount. In the event that facts and circumstances indicate that the cost of long-lived assets, primarily property, plant and equipment may be impaired, the Company performs a recoverability evaluation. If an evaluation is required, the undiscounted estimated future cash flows associated with the assets are compared to the assets' carrying amount to determine whether a write-down to fair value is required.

Impairment losses are measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risks associated with the recovery of the assets. Assets to be disposed of are reported at the lower of carrying amount or fair value less costs to sell.

Deferred Revenue The Company has entered into several distribution agreements which the distributor agreed to make certain upfront lump sum payments in exchange for certain distribution rights. These payments are recognized as revenue ratably to approximate services provided under the contract. Recognition of revenue commences over the term of the distribution agreement upon delivery of initial products. During 2006, Davol paid the Company \$3,300 in fees for exclusive distribution rights and for the commencement of the shipment of products. In addition, during 2006, Mentor agreed to pay the Company \$500 associated with the exclusive distribution rights and the attainment of certain terms and conditions. At September 30, 2006, \$250 has been paid to the Company.

Revenue and Cost of Revenue - Revenue includes amounts from surgical product sales, tissue service processing, and distribution fees. Cost of revenue includes depreciation of \$529, \$686, and \$311 for the years ended September 30, 2006, 2005 and 2004, respectively. Revenue on product sales is recognized when persuasive evidence of an arrangement exists, the price is fixed and final, delivery has occurred and there is a reasonable assurance of collection of the sales proceeds. Oral or written purchase authorizations are generally obtained from customers for a specified amount of product at a specified price. Revenue from surgical products is recognized upon the shipment of the processed tissues. The Company's terms of sale are FOB shipping point. Title transfers at time of shipment. Customers are provided with a limited right of return. Reasonable and reliable estimates of product returns are made in accordance with SFAS No. 48 and allowances for doubtful accounts are based on significant historical experience. Revenue from distribution fees includes nonrefundable payments received as a result of exclusive distribution agreements between the Company and independent distributors. Distribution fees under these arrangements are recognized as revenue to approximate services provided under the contract. Recognition of revenue commenced over the term of the distribution agreement upon delivery of initial products.

Research and Development Costs - Research and development costs are charged to operations as incurred.

Earnings Per Share - Basic earnings per share are computed by dividing net income (loss) by the weighted-average number of common shares outstanding. Diluted earnings per share are computed by dividing net income (loss) by the sum of the weighted-average number of common shares outstanding plus the potentially dilutive effect of shares issuable through the exercise of stock options and warrants or conversion of convertible debentures.

Table of Contents

Share-Based Compensation - We estimate the value of share-based payments on the date of grant using the Black-Scholes model, which was also used previously for the purpose of providing pro forma financial information as required under SFAS 123. The determination of the fair value of, and the timing of expense relating to, share-based payment awards on the date of grant using the Black-Scholes model is affected by our stock price as well as assumptions regarding a number of variables including the expected term of awards, expected stock price volatility and expected forfeitures.

Use of Estimates - The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates related to the value of share-based compensation, inventory, accounts receivable, and deferred tax assets and liabilities are made by management at each reporting period. Actual results could differ from those estimates.

Comprehensive Income (Loss) - The Company follows Statement of Financial Accounting Standard (SFAS) No. 130, REPORTING COMPREHENSIVE INCOME (LOSS). Comprehensive income is defined as the total change in shareholders' equity during the period other than from transactions with shareholders, and for the Company, includes net income and cumulative translation adjustments.

Income Taxes - Deferred taxes are provided for the expected future income tax consequences of events that have been recognized in the Company's financial statements. Deferred tax assets and liabilities are determined based on the temporary differences between the financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates in effect in the years in which the temporary differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to amounts, which are more likely than not to be realized.

The Company records valuation allowances to reduce the deferred tax assets to the amounts estimated to be recognized. While we consider taxable income in assessing the need for a valuation allowance, in the event we determine it is more-likely-than-not we would be able to realize our deferred tax assets in the future, an adjustment to the valuation allowance would be made and income increased in the period of such determination. Likewise, in the event we determine we would not be able to realize all or part of our deferred tax assets in the future, an adjustment to the valuation allowance would be made and charged to income in the period of such determination.

Employee Savings Plan - The Company maintains the Tutogen Medical, Inc. 401(k) Plan (the Plan) for which all of the United States employees are eligible. The Plan requires the attainment of the age of 21 and a minimum of six months of employment to become a participant. Participants may contribute up to the maximum dollar limit set by the Internal Revenue Service. The expenses incurred for the Plan were \$95, \$57 and \$73 in 2006, 2005 and 2004, respectively.

Reclassification - Certain reclassifications have been made to the prior financial statements to conform to the current presentation, including reclassing certain insurance premium costs previously expensed in cost of revenue to general and administrative expenses, and splitting out the previous balance sheet line item accounts payable and other accrued expenses into separate line items of accounts payable and accrued expenses and other current liabilities.

3. NEW ACCOUNTING PRONOUNCEMENTS

In November 2004, the FASB issued SFAS No. 151, INVENTORY COSTS, AN AMENDMENT OF ARB NO. 43. SFAS No. 151, which requires idle facility expenses, freight, handling costs, and wasted material (spoilage) costs to be excluded from the cost of inventory and expensed when incurred. It also requires that allocation of fixed overheads to the costs of conversion be based on the normal capacity of the production facilities. This statement was effective for inventory costs incurred during fiscal years beginning after June 15, 2005. The adoption of SFAS No. 151, effective at the beginning of year ended September 30, 2006, had no material impact on the Company's financial statements.

Table of Contents

In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS No. 123R, SHARE-BASED PAYMENT, that requires compensation costs related to share-based payment transactions to be recognized in the financial statements. The Company began complying with SFAS No. 123R at the beginning of the fiscal year ended September 30, 2006. In March 2005, the Securities and Exchange Commission (the SEC) issued Staff Accounting Bulletin (SAB) No. 107, SHARE-BASED PAYMENT, which provides interpretive guidance related to the interaction between SFAS No. 123R and certain SEC rules and regulations, as well as provides the SEC staff's views regarding the valuation of share-based payment arrangements. See Note 4, STOCK-BASED COMPENSATION, regarding the impact of these pronouncements on the Company's financial statements.

In May of 2005, the FASB issued SFAS 154, ACCOUNTING CHANGES AND ERROR CORRECTIONS. This statement replaces APB Opinion 20, ACCOUNTING CHANGES, and SFAS 3, REPORTING ACCOUNTING CHANGES IN INTERIM FINANCIAL STATEMENTS. This statement changes the requirements for the accounting for and reporting of a change in accounting principle, and applies to all voluntary changes in accounting principle. This statement also applies to changes required by an accounting pronouncement in the unusual instance that the pronouncement does not include specific transition provisions. Previously, APB Opinion 20 required that most voluntary changes in accounting principle be recognized by including in net income of the period of the change the cumulative effect of changing to the new accounting principle. SFAS 154 requires retrospective application to prior periods' financial statements of changes in accounting principle, unless it is impracticable to determine either the period-specific effects or the cumulative effect of the change. This statement is effective for accounting changes and corrections of errors made in fiscal years beginning after December 15, 2005. The adoption of this standard is not expected to have a material impact on the Company's financial statements.

In June of 2006, the FASB issued FASB Interpretation (FIN) No. 48 ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. This interpretation clarifies the accounting for uncertainty in income taxes recognized in an enterprise's financial statements in accordance with SFAS 109. This interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Under this interpretation, the evaluation of a tax position is a two-step process. First, the enterprise determines whether it is more-likely-than-not that a tax position will be sustained upon examination, based on the technical merits of the position. The second step is measuring the benefit to be recorded from tax positions that meet the more-likely-than-not recognition threshold, whereby the enterprise determines the largest amount of tax benefit that is greater than 50 percent likely of being realized upon ultimate settlement, and recognizes that benefit in its financial statements. FIN 48 also provides guidance on recognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006. Management has not yet determined the impact this pronouncement will have on the Company's financial statements.

In September 2006, the FASB issued SFAS 157, FAIR VALUE MEASUREMENTS. This standard defines fair value, establishes a framework for measuring fair value in accounting principles generally accepted in the United States (GAAP), and expands disclosures about fair value measurements. This standard is effective for financial statements issued for fiscal years beginning after November 15, 2007. The Company is currently evaluating the requirements of SFAS 157 and has not yet determined the impact on the Company's financial statements.

In September 2006, the FASB issued SFAS 158, EMPLOYERS' ACCOUNTING FOR DEFINED BENEFIT PENSION AND OTHER POSTRETIREMENT PLANS - An Amendment of SFAS Nos. 87, 88, 106 and 132(R). This standard requires an employer to recognize the overfunded or underfunded status of a defined benefit postretirement plan as an asset or liability in its statement of financial position and to recognize changes in that funded status in the year in which the changes occur as a component of comprehensive income. The standard also requires an employer to measure the funded status of a plan as of the date of its year-end statement of financial position. The requirement to recognize the funded status of a defined benefit postretirement plan is effective as of the end of the fiscal year ending after December 15, 2006. The adoption of SFAS 158 is not expected to have a material impact on the Company's financial statements.

Table of Contents

In September 2006, the SEC staff issued Staff Accounting Bulletin No. 108, CONSIDERING THE EFFECTS OF PRIOR YEAR MISTATEMENTS WHEN QUANTIFYING MISSTATEMENTS IN CURRENT YEAR FINANCIAL STATEMENTS. SAB 108 eliminates the diversity of practice surrounding how public companies quantify financial statement misstatements. It establishes an approach that requires quantification of financial statement misstatements based on the effects of the misstatements on each of the Company's financial statements and the related financial statement disclosures. SAB 108 must be applied to annual financial statements for their first fiscal year ending after November 15, 2006. Management does not believe the adoption of this standard will have a material impact on the Company's financial statements.

4. SHAREHOLDERS EQUITY AND STOCK-BASED COMPENSATION

STOCK The authorized stock of the Company consists of 30,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock.

PREFERRED SHARE PURCHASE RIGHT On July 17, 2002, the Board of Directors of the Company declared a dividend distribution of one Preferred Share Purchase Right for each outstanding share of its common stock of record on July 31, 2002. The rights, which expire on July 30, 2012, are designed to assure that all of the Company's shareholders receive fair and equal treatment in the event of any proposed takeover of the Company. Each right will entitle its holder to purchase, at the right's then current exercise price, a number of the Company's common shares having a market value of twice such price.

STOCK OPTION PLANS The Company maintains the 1996 Stock Option Plan (the Plan) (4,000,000 shares authorized) under which incentive and nonqualified options have been granted to employees, directors and certain key affiliates. Under the Plan, options may be granted at not less than the fair market value on the date of grant. Options may be subject to a vesting schedule and expire four, five or ten years from grant. This plan remains in effect for all options issued during its life.

The Plan was superseded by the Tutogen Medical Inc. Incentive and Non-Statutory Stock Option Plan (the New Plan) (1,000,000 shares authorized), adopted by the Board of Directors on December 5, 2005 and ratified by the shareholders on March 13, 2006. Under the New Plan, options may be granted at not less than the fair market value on the date of grant. Options may be subject to a vesting schedule and expire four, five or ten years from grant.

Effective October 1, 2005, the Company adopted the provisions of SFAS No. 123R which establishes the financial accounting and reporting standards for stock-based compensation plans. SFAS No. 123R requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors. Under the provisions of SFAS No. 123R, stock-based compensation cost is measured at the grant date, based on the calculated fair value of the award, and is recognized as an expense over the requisite service period of the entire award (generally the vesting period of the award). As a result of adopting SFAS No. 123R, the Company's net loss before income taxes and net loss for the year ended September 30, 2006 was \$451 more than if the Company had continued to account for stock-based compensation under Accounting Principles Board Opinion (APB) No. 25, ACCOUNTING FOR STOCK ISSUED TO EMPLOYEES and its related interpretations. Basic and diluted net loss per share for the year ended September 30, 2006 was \$.03 more than if the Company had continued to account for stock-based compensation under APB 25. In addition, there was no statement of cash flow or tax effect related to the adoption of SFAS No. 123R due to the recording of a full valuation allowance against U.S. net deferred tax assets.

The Company elected to use the modified prospective transition method as permitted by SFAS No. 123R and, therefore, financial results for prior periods have not been restated. Under this transition method, stock-based compensation expense for the year ended September 30, 2006 includes expense for all equity awards granted prior

to, but not yet vested as of October 1, 2005, based on the grant date fair value estimated in accordance with the original provisions of SFAS No. 123, ACCOUNTING FOR STOCK-BASED COMPENSATION as amended by SFAS No. 148, ACCOUNTING FOR STOCK-BASED COMPENSATION TRANSITION AND DISCLOSURE. Since the adoption of SFAS No. 123R, there have been no changes to the Company's stock compensation plans or modifications to outstanding stock-based awards which would increase the value of any

F-10

Table of Contents

awards outstanding. Compensation expense for all stock-based compensation awards granted subsequent to October 1, 2005 was based on the grant-date fair value determined in accordance with the provisions of SFAS No. 123R. During the year ended September 30, 2006, the Company recognized compensation expense of \$451 relating to stock options granted during the year ended September 30, 2006 in addition to the vesting of options outstanding as of October 1, 2005. All such expense was recognized within General and administrative expense in the Statement of Operations. There were no significant capitalized stock-based compensation costs at September 30, 2006.

Prior to October 1, 2005, the Company accounted for stock-based compensation in accordance with APB 25 and also followed the disclosure requirements of SFAS No. 123. Under APB 25, the Company accounted for stock-based awards to employees and directors using the intrinsic value method as allowed under SFAS No. 123. Under the intrinsic value method, no stock-based compensation expense had been recognized in the Company's Statement of Operations because the exercise price of the Company's stock options granted to employees and directors equaled the fair market value of the underlying stock at the date of grant.

The following table reconciles net income (loss) and basic and diluted earnings (loss) per share (EPS), as reported, to pro-forma net income (loss) and basic and diluted EPS, as if the Company had expensed the fair value of stock options.

Net (loss) income	2005 (\$7,017)	2004 \$ 1,133
Deduct: Total stock-based employee compensation expense determined under fair value based method, net of related tax effects	102	159
Pro-forma net (loss) income	(\$7,119)	\$ 974
Basic EPS:		
As reported	(\$ 0.44)	\$ 0.07
Pro-forma	(\$ 0.45)	\$ 0.06
Diluted EPS:		
As reported	(\$ 0.44)	\$ 0.07
Pro-forma	(\$ 0.45)	\$ 0.06

The fair value of each stock option grant is estimated on the grant date using the Black-Scholes option-pricing model with the following assumptions:

	September 30, 2006	September 30, 2005	September 30, 2004
Expected volatility	50.2%	47%	47%
Risk-free interest rate (range)	4.5%-4.7%	2.26%-3.12%	2.26%-3.12%
Expected term (in years)	5	5	4

F-11

Table of Contents

EXPECTED VOLATILITY. The Company's methodology for computing the expected volatility is based solely on the Company's historical volatility.

EXPECTED TERM. The expected term is based on employee exercise patterns during the Company's history and expectations of employee exercise behavior in the future giving consideration to the contractual terms of the stock-based awards.

RISK-FREE INTEREST RATE. The interest rate used in valuing awards is based on the yield at the time of grant of a U.S. Treasury security with an equivalent remaining term.

DIVIDEND YIELD. The Company has never paid cash dividends, and does not currently intend to pay cash dividends, and thus has assumed a 0% dividend yield.

PRE-VESTING FORFEITURES. Estimates of pre-vesting option forfeitures of 10% are based on Company experience and industry trends. The Company will adjust its estimate of forfeitures over the requisite service period based on the extent to which actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of compensation expense to be recognized in future periods.

Presented below is a summary of the status of the Company's stock options as of September 30, 2006 and related transactions for the years then ended:

	Number of Common Shares	Weighted Average Exercise Price
Outstanding at September 30, 2003	2,256,368	\$ 2.52
Granted	225,000	\$ 3.98
Canceled	(93,750)	\$ 4.45
Exercised	(248,850)	\$ 1.47
Outstanding at September 30, 2004	2,138,768	\$ 2.72
Granted	622,000	\$ 2.99
Canceled	(262,400)	\$ 4.03
Exercised	(17,000)	\$ 2.17
Outstanding at September 30, 2005	2,481,368	\$ 2.64
Granted	125,000	\$ 3.34
Canceled	(103,225)	\$ 3.84
Exercised	(264,275)	\$ 2.45
Outstanding at September 30, 2006	2,238,868	\$ 2.65
Vested or expected to vest	2,014,981	\$ 2.65
Fully Vested at September 30, 2006	1,781,493	\$ 2.55

As of September 30, 2006, 982,500 stock options were available for grant.

The following table provides information about stock options outstanding at September 30, 2006:

F-12

Table of Contents

RANGE OF EXERCISE PRICE	OPTIONS OUTSTANDING			OPTIONS EXERCISABLE	
	NUMBER	CONTRACTUAL	AVERAGE	NUMBER	WEIGHTED-
	OUTSTANDING	LIFE	EXERCISE	EXERCISABLE	EXERCISE
	AS OF	(IN	PRICE	AS OF	PRICE
	9/30/06	YEARS)		9/30/06	
\$0.94 to \$1.25	284,600	2.9	0.95	284,600	0.95
\$1.56 to \$2.22	536,568	1.7	1.76	529,068	1.76
\$2.28 to \$3.62	992,500	6.7	2.82	641,875	2.87
\$3.95 to \$11.00	425,200	5.4	4.41	325,950	4.60
\$0.94 to \$11.00	2,238,868	4.80	2.65	1,781,493	2.55

As of September 30, 2006, there was \$371 of total unrecognized compensation cost related to nonvested stock options. That cost is expected to be recognized over a weighted-average period of 1.53 years. The intrinsic value of options exercised during the years ended September 30, 2006, 2005 and 2004 were \$561, \$23, and \$614, respectively. The total aggregate intrinsic value of options outstanding for the years ended September 30, 2006, 2005 and 2004 were \$4,151, \$4,765 and \$608, respectively. The total aggregate intrinsic value of exercisable options outstanding for the years ended September 30, 2006, 2005 and 2004 were \$3,479, \$3,861 and \$734, respectively. For the year ended September 30, 2006, the total fair market value of shares vested was \$361. The weighted average fair value of options granted during the years ended September 30, 2006, 2005 and 2004 was \$1.62, \$1.38 and \$1.82, respectively.

5. CONCENTRATION OF RISK

Distribution The majority of the Company's revenues are derived through the Company's relationships with two companies, Zimmer Dental and Zimmer Spine which distributed approximately 46% and 8%, respectively, of the Company's consolidated revenues during 2006. Zimmer Dental markets our products to the end user and the Company ships and bills the customer directly. If the Company's relationship with Zimmer is terminated or further reduced for any reason and we are unable to replace the relationship with other means of distribution, the Company would suffer a material decrease in revenues.

Tissue Supply The Company's business is dependent on the availability of donated human cadaver tissues supplied by donor recovery groups. Allosource, our largest donor recovery group, supplied the Company with approximately 65% of our total human tissue for the year ended September 30, 2006. Our three largest recovery groups together supplied approximately 83% of our total human tissue during 2006. Any significant interruption in the availability of human tissue would likely cause the Company to slow down the processing and distribution of the Company's human tissue products, which could adversely affect the Company's ability to supply the needs of the Company's customers and materially and adversely affect the results of operations and the relationships with customers.

Trade Receivables As of September 30, 2006, one customer, Zimmer Spine, represented 15% of the Company's outstanding trade receivables. No other customer represented more than 10% of the Company's outstanding trade receivables.

6. INVENTORIES

Major classes of inventory at September 30, 2006 and 2005 were as follows:

	2006	2005
Raw Materials	\$ 2,017	\$ 1,228
Work in progress	5,811	4,943
Finished goods	4,850	3,383
	12,678	9,554

F-13

Table of Contents**7. PROPERTY, PLANT AND EQUIPMENT**

Property, plant and equipment at September 30, 2006 and 2005 consisted of the following:

	2006	2005
Land	\$ 522	\$ 495
Buildings and improvements	6,275	3,835
Machinery and equipment	5,174	2,329
Office furniture and other	1,284	2,787
Construction-in-progress	3,981	883
	17,236	10,329
Less accumulated depreciation	(4,296)	(3,717)
	\$ 12,940	\$ 6,612

The depreciation expense for the years ended September 30, 2006, 2005 and 2004 was \$778, \$984, and \$760, respectively.

8. SEVERANCE COSTS

During the year ended September 30, 2006, the Company accrued compensation expense of \$437 for severance costs upon the termination of the Managing Director of the Company's German subsidiary. These costs are a component of general and administrative expenses in the Consolidated Statement of (Loss) Income and Comprehensive (Loss) Income for the year ended September 30, 2006, and the accrual for these costs is included in Accrued expenses and other current liabilities in the Consolidated Balance Sheet as of September 30, 2006. These severance costs are being paid in twelve monthly equal payments during the period from July 1, 2006 through June 30, 2007. As of September 30, 2006, the remaining accrual is \$334.

9. REVOLVING CREDIT ARRANGEMENTS AND SHORT TERM BORROWINGS

Under the terms of revolving credit facilities with two German banks, the Company may borrow up to 1,500 Euros (1,000 Euros and 500 Euros, respectively) or approximately \$1,900 for working capital needs. These renewable credit lines allow the Company to borrow at interest rates ranging from 8.05% to 9.5%. At September 30, 2006 the Company had outstanding borrowings of 819 Euros or \$1,039. At September 30, 2005, the Company had no borrowings under the revolving credit agreements. The 500 Euro revolving credit facility is secured by accounts receivable of the German subsidiary. The 1,000 Euro revolving credit facility is secured by a mortgage on the Company's German facility and a guarantee by the parent Company.

In November 2005, the Company entered into a revolving credit facility in the U.S. for up to \$1,500, expiring on November 18, 2007. At September 30, 2006, the interest rate on this credit facility was 8.3%. At September 30, 2006, the Company had outstanding \$1,500 on this credit facility to fund working capital needs. The U.S. accounts receivable and inventory assets collateralize the borrowing under the revolving credit facility. The Company is required to maintain a maximum senior debt to tangible net worth ratio of 2.0 to 1.0. As of September 30, 2006, the Company was in compliance with this covenant. In addition, the Company maintains a lock box arrangement with the bank.

The Company prepays certain expenses including insurance premiums. From time to time, the Company enters into short term notes to finance insurance premiums. As of September 30, 2006, short term borrowings on the consolidated balance sheet included an outstanding balance of \$449 related to such activity.

On June 30, 2006, the Company issued a \$3,000 convertible debenture with detachable warrants to purchase up to 175,000 shares of its common stock. The debenture bears interest at 5.0% per year, is due upon the earlier of August 1, 2007, or upon a change of control of the Company and is convertible into common stock at a price of \$5.15 per share at any time at the election of the holder. The warrants are exercisable at \$5.15 per share at any time at the

election of the shareholder until the earlier of the third anniversary of the date of issuance or upon a change in control of the Company. The convertible debt is included in short-term borrowings on the Consolidated Balance Sheet at September 30, 2006. As of September 30, 2006, the Company was in compliance with the terms and conditions of the convertible debenture.

F-14

Table of Contents

The relative fair value of the detachable warrants at inception of the convertible debenture agreement was \$275 and was computed using the Black-Scholes pricing model under the following assumptions: (1) expected life of 3 years; (2) volatility of 53.5%, (3) risk free interest of 5.13% and dividend yield of 0%. The proceeds of the convertible debenture were allocated to debt and warrants based on their relative fair values. The relative fair value of the warrants was recorded to additional paid-in capital and resulted in a discount on the convertible debenture, which will be amortized to interest expense over the one-year term of the debenture. The remaining unamortized balance of the warrants as of September 30, 2006 is \$205. The convertible debenture balance of \$2,725, net of debt discount, is included in short-term borrowings. In addition, \$205 of direct costs incurred relating to the issuance of the convertible debenture was recorded as debt issuance costs in other current assets, which will also be amortized to interest expense over the one-year term of the debenture.

10. LONG-TERM DEBT

Long-term debt at September 30, 2006 and 2005 consisted of the following:

	2006	2005
Senior debt	\$ 3,635	\$ 651
Capital lease	1,135	163
	4,770	814
Less current portion	(1,097)	(184)
	\$ 3,673	\$ 630

Aggregate maturities of senior debt are \$480 in 2007; \$515 in 2008; \$533 in 2009; \$545 in 2010; \$482 in 2011; and \$1,080 beyond 2011.

The Senior debt consists of two loans with a German bank. The first loan (\$576 as of September 30, 2006) has an interest rate of 5.75%, payable monthly, maturing March of 2011. The second loan (\$1,744 as of September 30, 2006) has an interest rate of 5.15%, payable quarterly, maturing March of 2012.

The Senior debt, refinanced construction line of credit, and a revolving credit facility with a German bank are secured by a mortgage on the Company's German facility and is guaranteed up to 4 million euros by the parent company.

There are no financial covenants under this debt.

At September 30, 2006, the Company had an interim construction loan of 1,037 Euros or approximately \$1,316, at an annual interest rate of 5.75%, to finance its facility expansion project in Germany. The interim loan was converted to a long-term loan November 30, 2006. This loan has a 10 year term, payable semi-annually (60 Euros) at a fixed rate of 5.6%.

The Capital lease debt consists of two leases. The first lease (initial cost of \$1,300, with \$250 of accumulated amortization as of September 30, 2006) is payable monthly at \$55 per month and matures April of 2008. The lease is secured by leasehold improvements and equipment located at the Company's Florida tissue processing facility. The second lease (initial cost of \$224, with \$139 of accumulated amortization as of September 30, 2006) is payable at \$22 quarterly and matures September of 2007. The lease is secured by equipment located at the Company's Florida tissue processing facility. As of September 30, 2006, the Company is in compliance with the terms and conditions of the Capital lease debt. Capital lease assets and related liabilities are included within the captions Property, plant, and equipment, net and Long-term debt on the accompanying consolidated balance sheet. The table below represents the future minimum capital lease payments.

Total	2007	2008
-------	------	------

Edgar Filing: TUTOGEN MEDICAL INC - Form S-1

Principal	\$ 1,135	\$ 617	\$ 518
Interest	170	135	35
Total	\$ 1,305	\$ 752	\$ 553

F-15

Table of Contents

For the year ended September 30, 2006, \$987 related to a non-cash capital lease agreement has been excluded from the purchase of property and equipment, and proceeds from long-term borrowings on the accompanying consolidated statement of cash flows.

For the year ended September 30, 2006, the Company incurred interest costs of \$578. Of this amount, \$285 was capitalized to property, plant and equipment for assets constructed during the year and \$293 was charged to interest expense.

11. DERIVATIVE INSTRUMENTS

The Company accounts for its hedging activities in accordance with SFAS No. 133, ACCOUNTING FOR DERIVATIVES AND HEDGING ACTIVITIES, as amended. SFAS No. 133 requires that all hedging activities be recognized in the balance sheet as assets or liabilities and be measured at fair value. Gains or losses from the change in fair value of hedging instruments that qualify for hedge accounting are recorded in other comprehensive income. The Company's policy is to specifically identify the assets, liabilities or future commitments being hedged and monitor the hedge to determine if it continues to be effective. The Company does not enter into or hold derivative instruments for trading or speculative purposes. The fair value of the Company's interest rate swap agreement for its 1,500 Euro (\$1,900) long-term loan is based on dealer quotes and was not significant as of September 30, 2006. The construction loan payable is due on March 30, 2012 in monthly installments of approximately \$78 (63 Euros) including principal and interest based on an adjustable rate as determined by one month EURIBOR, fixed by a swap agreement for the life of the loan with the lender at 3.7% as a cash flow hedge. The proceeds were used to construct new facilities. As indicated in Note 9, on June 30, 2006, the Company issued a \$3,000 convertible debenture which contained features that qualify as embedded derivatives that require bifurcation, however, the value ascribed to these features was determined to be de-minimus to the overall financial statement presentation and accordingly, value was not allocated to these features and the carrying value of the convertible debenture was not reduced. As of September 30, 2006, the estimated change in the fair values of these features remained a de-minimus amount.

12. SEGMENT DATA

The Company operates principally in one industry providing specialty surgical products and tissue processing services. These operations include two geographically determined segments: the United States and Europe (International). The accounting policies of these segments are the same as those described in the summary of significant accounting policies. The Company evaluates performance based on the operating income of each segment. The Company accounts for intersegment sales and transfers at contractually agreed-upon prices.

Table of Contents

The Company's reportable segments are strategic business units that offer products and services to different geographic markets. They are managed separately because of the differences in these markets as well as their physical location.

A summary of the operations and assets by segment as of and for the years ended September 30, 2006, 2005 and 2004 are as follows:

2006	INTERNATIONAL	UNITED STATES	CONSOLIDATED
Gross revenue	\$ 16,039	\$ 25,430	\$ 41,469
Less intercompany	(3,522)		(3,522)
Total revenue third party	\$ 12,517	\$ 25,430	\$ 37,947
Depreciation and amortization	\$ 471	\$ 307	\$ 778
Operating income (loss)	\$ 168	\$ (455)	\$ (287)
Interest expense	\$ 81	\$ 212	\$ 293
Income tax benefit	\$ (194)	\$ 0	\$ (194)
Net income (loss)	\$ 332	\$ (921)	\$ (589)
Capital expenditures	\$ 3,248	\$ 2,742	\$ 5,990
Identifiable assets	\$ 18,477	\$ 20,440	\$ 38,917
2005	INTERNATIONAL	UNITED STATES	CONSOLIDATED
Gross revenue	\$ 17,344	\$ 21,752	\$ 39,096
Less intercompany	(7,236)		(7,236)
Total revenue third party	\$ 10,108	\$ 21,752	\$ 31,860
Depreciation and amortization	\$ 615	\$ 369	\$ 984
Operating Loss	\$ (974)	\$ (6,253)	\$ (7,227)
Interest expense	\$ 61	\$ 69	\$ 130

Edgar Filing: TUTOGEN MEDICAL INC - Form S-1

Income tax benefit	\$	(436)	\$	0	\$	(436)
Net Loss	\$	(1,037)	\$	(5,980)	\$	(7,017)
Capital expenditures	\$	1,468	\$	213	\$	1,682
Identifiable assets	\$	16,200	\$	10,005	\$	26,205
2004				UNITED		
		INTERNATIONAL		STATES		CONSOLIDATED
Gross revenue	\$	22,830	\$	17,126	\$	39,956
Less intercompany		(10,626)				(10,626)
Total revenue third party	\$	12,204	\$	17,126	\$	29,330
Depreciation and amortization	\$	506	\$	254	\$	760
Operating income (loss)	\$	4,179	\$	(1,021)	\$	3,158
Interest expense	\$	79	\$	39	\$	118
Income tax expense	\$	1,306	\$	0	\$	1,306
Net income (loss)	\$	2,289	\$	(1,156)	\$	1,133
Capital expenditures	\$	1,244	\$	515	\$	1,758
Identifiable assets	\$	18,166	\$	15,370	\$	33,536

Total International long-lived assets of \$8,995, \$5,912, and \$5,282 for the years ended September 30, 2006, 2005 and 2004, respectively are located in Germany.

F-17

Table of Contents

A summary of revenues by segment for the years ended September 30, 2006, 2005 and 2004 are as follows:

	FY 2006	FY 2005	FY 2004
Dental	\$ 17,616	\$ 13,785	\$ 6,893
Spine	2,877	3,128	4,850
Surgical Specialties	4,937	4,839	5,383
Total U.S.	\$ 25,430	\$ 21,752	\$ 17,126
Germany	\$ 2,851	\$ 1,980	\$ 3,521
Rest of World (ROW)	7,472	6,220	6,001
France	1,672	1,337	2,121
Other Distribution Fees	522	571	561
Total-International	\$ 12,517	\$ 10,108	\$ 12,204
Total Consolidated	\$ 37,947	\$ 31,860	\$ 29,330

13. INCOME TAXES

The (benefit) provision for income taxes for the years ended September 30, 2006, 2005 and 2004 are summarized as follows:

	2006	2005	2004
Current:			
Federal	\$ 8	\$	\$
State			
Foreign	(953)		1,153
	(945)		1,153
Deferred:			
Federal	116	(2,260)	(737)
State	19	(194)	(162)
Foreign	759	(571)	153
	894	(3,025)	(746)
Valuation allowance	(143)	2,589	899
(Benefit) provision for income taxes	\$ (194)	\$ (436)	\$ 1,306

Table of Contents

The differences between the U.S. statutory rates and those in the consolidated statements of (loss) income and comprehensive (loss) income are primarily due to the foreign entity being taxed at a lower rate and certain nondeductible items, as follows.

	2006	2005	2004
Income (benefit) tax at federal statutory rate (34%)	\$ (250)	\$ (2,536)	\$ 854
State tax	10	(194)	(162)
Valuation allowance	(143)	2,589	899
Foreign tax differential	(3)	(303)	(293)
Foreign exchange loss	(364)		
Stock options	124		
Foreign dividend income	423		
Other	9	8	8
Total	\$ (194)	\$ (436)	\$ 1,306

The tax effect of the temporary differences that give rise to the Company's net deferred taxes as of September 30, 2006, and 2005 are as follows:

	2006	2005
Deferred tax assets:		
Current:		
Other liabilities	\$ 2	\$ 70
Management fees	576	402
Bad debt reserve	53	44
Inventory reserve	545	594
Vacation pay	53	
Stock options	34	
Distribution fees	19	
Insurance reserve	117	39
Subtotal	1,399	1,149
Noncurrent:		
Net operating loss carryforward and tax credits	6,737	7,006
Distribution fees	38	786
Other liabilities	17	70
Deferred tax asset	8,191	9,011
Deferred tax liability:		
Noncurrent:		
Fixed assets	(252)	(225)
Deferred revenue		(96)

Subtotal	(252)	(321)
Valuation allowance	(6,166)	(6,309)
Net deferred tax asset	\$ 1,773	\$ 2,381

F-19

Table of Contents

During 2006, the Company had approximately \$192 (\$65 tax effected) related to current year excess tax deductions from the exercise of nonqualified stock options. Because the Company has net operating loss carryforwards, the Company has not yet realized the tax benefit from the nonqualified stock option deduction. Pursuant to SFAS No. 123R, this excess tax benefit is not included as a component of the Company's deferred tax assets, as realization of the benefit has not yet occurred. Therefore, the \$65 of excess tax benefit is not reflected in the net operating loss and credit amount in the above deferred tax asset schedule.

The Company has recorded a valuation allowance to reflect the estimated amount of deferred tax assets that may not be realized due to the expiration of net operating losses and tax credit carryovers. The net decrease in the valuation allowance is comprised primarily of the utilization of federal and state net operating loss carryforwards to offset current year taxable income.

As of September 30, 2006, the Company has approximately \$13,281 of federal net operating loss carry forwards expiring beginning in 2009, a \$29 AMT credit carry forward, and a \$21 credit on research and development that will expire in 2013 if unused. The Company also has state net operating loss carry forwards of approximately \$12,784 that will begin to expire in 2007.

As of September 30, 2006, the Company has a corporate net operating loss carry forward for German income tax purposes of approximately \$4,114 (3,242 Euros), and a trade net operation loss carry forward for German income tax purposes of approximately \$2,139 (1,686 Euros), which can be carried forward indefinitely. The Company continually reviews the adequacy and necessity of the valuation allowance in accordance with the provisions of SFAS No. 109, ACCOUNTING FOR INCOME TAXES. As of September 30, 2006, the Company has recorded a valuation allowance on deferred tax assets related to its U.S. operations. The Company does not maintain a valuation allowance on its international deferred tax assets, because management believes it is more likely than not that these tax benefits will be realized through the generation of future international taxable income.

Historically, the Company has not recorded deferred income taxes on the undistributed earnings of its foreign subsidiaries because it is management's intent to indefinitely reinvest such earnings. During 2006, the Company eliminated certain intercompany accounts, requiring the utilization of some undistributed earnings of its German subsidiary. The resulting tax was absorbed by the utilization of net operating loss carryforwards.

Going forward, the Company does not intend to record deferred income taxes on future undistributed earnings of its foreign subsidiaries because it is management's intent to indefinitely reinvest such earnings. Upon distribution of these earnings, the Company may be subject to U.S. income taxes and/or foreign withholding taxes.

Table of Contents**14. EARNINGS PER SHARE**

The following is a reconciliation of the numerators and denominators of the basic and diluted (loss) earnings per share computations for the years ended September 30, 2006, 2005 and 2004. The Company has excluded 1,457,000, 419,000 and 367,000 shares of stock as such stock are anti-dilutive to the calculation:

<i>(in thousands, except share and per share amount data)</i>	Net (Loss) Income	Shares	Per Share Amount
2006			
Basic earnings per share	\$ (589)	16,027,469	\$ (0.04)
Effect of dilutive securities: Stock options, warrants and convertible debentures			
Diluted earnings per share	\$ (589)	16,027,469	\$ (0.04)
2005			
Basic loss per share	\$ (7,017)	15,919,286	\$ (0.44)
Effect of dilutive securities: Stock options			
Diluted loss per share	\$ (7,017)	15,919,286	\$ (0.44)
2004			
Basic earnings per share	\$ 1,133	15,734,470	\$ 0.07
Effect of dilutive securities: Stock options		734,973	
Diluted earnings per share	\$ 1,133	16,469,443	\$ 0.07

15. COMMITMENTS AND CONTINGENCIES

The Company currently has operating leases for its corporate offices in the U.S. and Germany, as well as several leases related to office equipment and automobiles. Total rental expense was \$959, \$1,212, and \$1,103 for the years ended September 30, 2006, 2005 and 2004, respectively. Future minimum rental payments required under these leases that have initial or remaining noncancelable lease terms in excess of one year as of September 30, 2006 are as follows:

2007	\$ 988
2008	748
2009	343

2010
Thereafter

32

\$2,111

F-21

Table of Contents

The Company is party to various claims, legal actions, complaints and administrative proceedings arising in the ordinary course of business. In management's opinion, the ultimate disposition of these matters will not have a material adverse effect on its financial condition, cash flows or results of operations. In 2003, the Company received a proposed judgment in Germany as the result of a dispute between the Company and a former international distributor. The estimated settlement, including legal costs was accrued as a litigation contingency. In 2004, a decision by the court of appeal in Germany has resulted in a reduction of the original proposed judgment received against the Company by \$406. At September 30, 2005 the Company maintained an accrual of \$476 with respect to the remaining appeal and legal costs. At September 30, 2006, the Company agreed to a settlement of \$360. As a result of the settlement the Company recorded a change in estimate of approximately \$91 as a reduction of accrued expenses, which reduced the operating loss for the year ended September 30, 2006. The remaining accrual will be used to settle final nominal legal and court costs.

On October 12, 2005, the Company issued a voluntary recall of all product units, which utilized donor tissue received from BioMedical Tissue Services/BioTissue Recovery Services (BioMedical). This action was taken because the Company was unable to satisfactorily confirm that BioMedical had properly obtained donor consent. The Company quarantined all BioMedical products in its inventory, having a value of \$1,035 and notified all customers and distributors of record regarding this action. In connection with the recall, the Company wrote off \$174 of inventory during 2005, and reserved \$861 for quarantined inventory, which was written off at September 30, 2006. Additionally, as of September 30, 2005, the Company had accrued \$250 of related costs in connection with the recall. As of September 30, 2006, the accrual for these costs was \$0, due in part to actual payments made for such costs and in part to an adjustment made by management during the three months ended March 31, 2006 to reduce the accrual by approximately \$150 as a result of a change in management's estimate of other related costs. The effect of this adjustment was to reduce cost of revenue by approximately \$150.

In January 2006, the Company was named as one of several defendants in a class action suit related to the BioMedical recall. It is management's opinion that it is too early in the process to determine the effect of this class action on the financial condition of the Company. The Company intends to vigorously defend this matter.

16. RELATED PARTY

The Company has an exclusive license and distribution agreement with Zimmer Spine, a wholly owned subsidiary of Zimmer Holdings, Inc., whereby Zimmer Spine has been granted the right to act as the Company's exclusive distributor of bone tissue for spinal applications in the United States. For the years ended September 30, 2006, 2005 and 2004 product sales to Zimmer spine totaled \$2,877, \$3,128 and \$4,850, respectively. Accounts receivable from Zimmer Spine were \$952 and \$44 at September 30, 2006 and 2005, respectively.

The Company has also engaged Zimmer Dental, a wholly owned subsidiary of Zimmer Holdings, Inc., to act as an exclusive distributor for the Company's bone tissue for dental applications in the United States and certain international markets. Under this distribution agreement, the Company sells directly to Zimmer Dental's customers. For the years ended September 30, 2006, 2005 and 2004, Zimmer Dental was paid commissions aggregating approximately \$7,200, \$6,055 and \$3,213, respectively. Accounts payable to Zimmer Dental total \$1,918 and \$1,740 at September 30, 2006 and 2005, respectively.

Zimmer CEP (formerly Centerpulse) USA Holding Co., a subsidiary of Zimmer Holdings, Inc., is a 32% owner of the Company's outstanding shares of common stock.

On March 10, 2006, Zimmer Holdings Inc. (Zimmer) filed an amended Schedule 13 (d) expressing its intention to initiate discussions with the Company which could possibly include further investment by Zimmer in securities of the Company or the acquisition by Zimmer of some or all of the outstanding common stock of the Company. During the due diligence period in 2006, the Company incurred approximately \$262,000 in legal, accounting and other transaction related expenses. The transaction expenses are included as a component of general and administrative expenses.

On August 9, 2006, representatives of Zimmer Holdings, Inc. contacted management of the Company telephonically to propose to the Company a non-binding indication of interest (the Indication of Interest) with respect to a proposed acquisition of the Company at an indicative price range of \$5.00 - \$6.00 per share of Common Stock. Later on the same day, the Company contacted Zimmer and rejected the Indication of Interest. Zimmer has determined not to

pursue an acquisition of the Company at this time, but based on other factors deemed relevant by Zimmer, including, but not limited to, the price and availability of Common Stock, subsequent developments affecting Zimmer and the Company, the business prospects of Zimmer and the Company, general stock market and economic conditions and tax considerations, Zimmer may formulate other plans and/or make other proposals and take other actions with respect to its investment in the Company that it deems to be appropriate.

F-22

Table of Contents**17. SUBSEQUENT EVENT**

In November 2006, the Company entered into strategic tissue sourcing agreements with Regeneration Technologies, Inc., (RTI). Under the multi-year agreements, RTI has the first right of refusal to all of the tissue used in sports medicine surgeries recovered by Tutogen's recovery partners. The Company, in turn, has the first right of refusal to all dermis, fascia and pericardium recovered by RTI donor services agencies.

18. SELECTED QUARTERLY FINANCIAL DATA (Unaudited)

The following is a summary of unaudited quarterly financial results for the year ended September 30, 2006:

(IN THOUSANDS, EXCEPT PER SHARE DATA)	2006 QUARTER ENDED			
	DECEMBER 31,	MARCH 31,	JUNE 30,	SEPTEMBER 30,
Revenues	\$8,034	\$9,115	\$10,000	\$ 10,798
Gross Profit	4,705	5,098	4,780	7,028
Operating expenses	4,948	5,236	6,026	5,688
Operating (loss) income	(243)	(138)	(1,246)	1,340
Income tax (benefit) expense	(106)	(213)	(413)	538
Net (loss) income	(81)	22	(1,129)	599
Comprehensive (loss) income	(284)	421	(752)	489
(Loss) earnings per share				
Basic	\$ (0.01)	\$ 0.00	\$ (0.07)	\$ 0.04
Diluted	\$ (0.01)	\$ 0.00	\$ (0.07)	\$ 0.04

	2005 QUARTER ENDED			
	DECEMBER 31,	MARCH 31,	JUNE 30,	SEPTEMBER 30,
Revenues	\$ 7,073	\$ 7,554	\$ 9,281	\$ 7,952
Gross Profit	2,875	2,957	3,275	2,624
Operating expenses	4,337	4,621	4,779	5,221
Operating loss	(1,462)	(1,664)	(1,504)	(2,597)
Income tax (benefit) expense	(148)	(344)	88	(32)
Net loss	(1,914)	(1,129)	(1,278)	(2,696)
Comprehensive loss	(1,628)	(1,473)	(822)	(3,664)
Loss per share				
Basic	\$ (0.12)	\$ (0.07)	\$ (0.08)	\$ (0.17)

F-23

Table of Contents**PART II INFORMATION NOT REQUIRED IN PROSPECTUS****Item 24. Indemnification of Officers and Directors.**

The Registrant's by-laws provide as follows:

To the fullest extent permitted by law, the corporation shall indemnify any person who is or was a party, or is threatened to be made a party, to any threatened, pending or completed action, suit or other type of proceeding (other than an action by or in the right of the corporation), whether civil, criminal, administrative, investigative or otherwise, and whether formal or informal, by reason of the fact that such person is or was a director or officer of the corporation or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against judgments, amounts paid in settlement, penalties, fines (including an excise tax assessed with respect to any employee benefit plan) and expenses (including attorneys' fees, paralegals' fees and court costs) actually and reasonably incurred in connection with any such action, suit or other proceeding, including any appeal thereof, if such person acted in good faith and in a manner such person reasonably believed to be in, or not opposed to, the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person's conduct was unlawful. The termination of any such action, suit or other proceeding by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner that such person reasonably believed to be in, or not opposed to, the best interests of the corporation or, with respect to any criminal action or proceeding, had reasonable cause to believe that such person's conduct was unlawful.

Item 25. Other Expenses of Issuance and Distribution

The following table sets forth the itemized and expenses payable by us in connection with the issuance and distribution of the securities being registered hereunder. No expenses shall be borne by the selling shareholder. All of the amounts shown are estimates, except for the SEC registration fee.

SEC registration fee	\$ 580
Printing and engraving expenses	5,000
Accounting fees and expenses	55,000
Legal fees and expenses	50,000
Miscellaneous	10,000
 Total	 120,580

S-1

Table of Contents**Item 26. Recent Sales of Unregistered Securities**

On June 30, 2006, the Company issued to Azimuth Opportunity, Ltd. a \$3.0 million subordinated convertible debenture and a warrant for the purchase of up to 175,000 shares of common stock for gross proceeds of \$3.0 million.

Pursuant to the terms of the securities purchase agreement, the debenture was sold at a face value of \$3.0 million and the warrants are exercisable at a price of \$5.15 per share at any time at the election of the holder until the earlier of the third anniversary of the date of issuance or upon a change in control of the Company.

The debenture, which bears interest at the rate of five percent (5%) per year (payable quarterly in arrears), is due upon the earlier of twelve (12) months from the date of issuance or upon a change in control of the Company, and is convertible into common stock at a price of \$5.15 per share at any time at the election of the holder. The debenture is unsecured and ranks junior to all of the Company's existing indebtedness and senior to any additional indebtedness.

The Company relied upon the exemption from registration provided by Section 4(2) of the Securities Act of 1933 and Rule 506 promulgated thereunder.

Item 27. Exhibits and Financial Statement Schedules**(a) Exhibit****Number Description**

- | | |
|--------|--|
| 3.1(a) | Certificate of Incorporation ^(b) |
| 3.1(b) | Articles of Amendment increasing number of authorized shares of capital stock ^(c) |
| 3.1(c) | Articles of Amendment effecting a reverse stock split ^(c) |
| 3.2 | Amended and Restated Bylaws ^(d) |
| 4.1 | See Exhibits 3.1 and 3.2 for the provisions of the Articles of Incorporation and Bylaws of the Company that define the rights of holders of the Company's common stock |
| 5.1 | Opinion of Counsel ^(a) |
| 10.4 | 1996 Incentive and Non-Statutory Option Plan ^(e) |
| 10.5 | 2006 Incentive and Non-Statutory Option Plan ^(f) |
| 10.8 | Employment Agreement of Guy L. Mayer, dated December 6, 2004 ^(g) |
| 10.9 | Registration Rights Agreement dated June 30, 2006, by and between Tutogen Medical, Inc. and Azimuth Opportunity, Ltd. ^(h) |
| 10.10 | Five percent (5%) Subordinated Convertible Debenture of Tutogen Medical, Inc. dated June 30, 2006 in an aggregate principal amount of \$3,000,000 issued to Azimuth Opportunity, Ltd. ^(h) |

S-2

Table of Contents

Number	Description
10.11	Common stock Purchase Warrant dated June 30, 2006 issued to Azimuth Opportunity, Ltd. for the purchase of up to 175,000 shares of the common stock of Tutogen Medical, Inc. ^(h)
10.12	Securities Purchase Agreement dated June 30, 2006 by and between Tutogen Medical, Inc. and Azimuth Opportunity, Ltd. ^(h)
10.13	Shareholders Rights Agreement ⁽ⁱ⁾
10.14	Copy of Distribution Agreement between Tutogen Medical, Inc. and Zimmer Dental, Inc. ^{(a)(j)}
10.15	Copy of Distribution Agreement between Tutogen Medical, Inc. and Zimmer Spine, Inc. ^{(a)(j)}
10.16	Copy of Assignment Agreement between Centerpulse France S.A.S., Zimmer GmbH, and Tutogen Medical GmbH, effective July 12, 2005. ^(a)
21.1	Subsidiaries of the Registrant: Tutogen Medical GmbH Germany wholly owned
23.1	Consent of Independent Registered Public Accounting Firm ^(a)
23.2	Consent of Counsel (See Exhibit 5.1) ^(a)

(a) Filed herewith.

(b) Filed as Exhibit to Company's Registration Statement on Form 20-F effective October 2, 1987.

(c) Filed as an Exhibit to the Company's Form 10-K for the year ended September 30, 1997.

(d) Filed as Exhibit to Form 8-K Report August 16, 2006.

- (e) Filed as Exhibit to Form S-8 filed October 31, 1996.
- (f) Filed as Exhibit to Proxy Statement filed in connection with the Company's 2006 annual meeting of shareholders.
- (g) Filed as Exhibit to Form 10-K Report for year ended September 30, 2005.
- (h) Filed as Exhibit to Form 8-K Report July 6, 2006.
- (i) Filed as Exhibit to Form 8-K Report July 17, 2002.
- (j) Portions of this Exhibit have been omitted pursuant to Rule 406, are filed separately with the SEC, and are subject to a confidential treatment request.

(b) Financial Statement Schedules

Schedule II Valuation and Qualifying Accounts

All other Schedules are omitted because they are not required, or are not applicable, or the information is included in the consolidated financial statements or the notes thereto.

Item 28. Undertakings

The undersigned company hereby undertakes that it will:

(1) file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement to include:

- (a) any prospectus required by Section 10(a)(3) of the Securities Act;
- (b) reflect in the prospectus any facts or events which, individually or together, represent a fundamental change in the information in the registration statement. Notwithstanding the foregoing, any incre